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ABSTRACT 
  
Background: Osteoarthritis (OA) is a group of diseases of different causes that 
ultimately lead to synovitis, subchondral bone remodeling, and articular cartilage 
degeneration. OA commonly develops in the distal intertarsal (DIT) and tarsometatarsal 
(TMT) joints of performance horses. Currently, the most accurate method of identifying 
OA in these joints is a combination of thorough physical, lameness, and radiographic 
examinations. However, many horses may have pain attributed or localized to these joints 
with minimal radiographic changes present. A novel way to identify and classify the 
degree of OA is through the measurement of molecular biomarkers. Molecular 
biomarkers of OA reflect quantitative and dynamic variations associated with joint 
metabolism.  
Objectives: (1) define the direct and indirect biomarker concentrations in synovial 
fluid from the tibiotarsal, distal intertarsal, and tarsometatarsal joints in horses with 
varying degrees of tarsal OA, and (2) validate/refute that the biomarker concentrations in 
these joints increase with severity of OA in the distal joints as determined by a 
radiographs (all joints), MRI (PIT, DIT, TMT joints), arthroscopic evaluation/ gross 
pathology (TT joint), and (3) determine if biomarker concentrations in the TT synovial 
fluid (SF) can be used to evaluated OA severity in the DIT and TMT joints.  
Methods: A cohort study of 11 older horses (>8 years) with variable amounts of 
OA in the tarsal joints identified on radiographs were included.  The TT joints were 
examined by arthroscopy/gross examination.  The distal tarsal joints were examined by 
MRI.  Biomarkers BAP, CPII, C2C, CTX II, CS846 were examined in the distal tarsal 
joints; additional biomarkers C1,2C, IL-1β, IL-6, IL-8, IL-10, and TNFα were examined 
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in the TT joint. Various statistical analyses were used to determine association between 
imaging modalities and biomarkers to degrees of OA severity.    
Results: In the TT joint, C2C and IL-6 were the best biomarkers distinguishing 
OA severity. There was more pathology present in TT joints than could be seen on 
radiographs, suggesting that arthroscopic surgery is still the best method to evaluate TT 
joint OA.  In the distal tarsal joints, radiographs were better at distinguishing OA and 
correlated to the corresponding MRIs, but underestimated the degree of SCB bone 
sclerosis, and number and size of osteophytes in many of the cases.  MRI also provided 
information about cartilage damage and SCB hyperintensity.  The severity of SCB 
sclerosis and presence of SCB hyperintensity on MRI was a good indicator for separating 
moderate/severe from mild OA.  Of the biomarkers evaluated, the best at determining OA 
severity in the DIT joint were BAP, CPII, and C2C.  These biomarkers also correlated to 
subchondral bone hyperintensity on MRI.  In the TMT joint, CPII was the best biomarker 
to determine OA severity. No biomarker was identified in the SF in the TT joint capable 
of identifying OA in the distal tarsal joints. 
Conclusions: Biomarkers have the potential to be a valuable source of information 
about the OA disease process in the tarsal joints.  SF from the joint of interest must be 
collected.  Further research is needed with more horses.  To the author’s knowledge, this 
is the first study examining biomarkers in an older horse population and hopes it provides 
a template for forthcoming research.    
  
	 	 	 v		
Table of Contents 
Acknowledgements………………………………………………………………………...i 
Dedication…………………………………………………………………………………ii 
Abstract…………………………………………………………………………………...iii 
Table of Contents…………………………………………………………………………v 
List of Tables…………………………………………………………………..…………vi 
List of Figures…………………………………………………………………….………ix 
 
1. PRELIMINARY LITERATURE REVIEW A)	NORMAL	EQUINE	JOINT	ANATOMY	AND	PHYSIOLOGY…………………….……………….1		B)	PATHOPHYSIOLOGY	OF	OSTEOARTHRITIS………………………………………………………8		C)	DIRECT	BIOMARKERS	OF	OSTEOARTHRITIS………………………………………….……….17		D)	INDIRECT	BIOMARKERS	OF	OSTEOARTHRITIS…………………………………….……...…20	
 
2. CLINICAL CHALLENGE OF DETERMINING OSTEOARTHRITIS IN 
TIBIOTARSAL JOINTS OF OLDER HORSES: USE OF DIRECT AND INDIRECT 
BIOMARKERS TO DETERMINE THE PRESENCE AND SEVERITY OF DISEASE ………………………………………………………………………………………………………………….………23 
 
3. THE USE OF BIOMARKERS TO DETERMINE THE SEVERITY OF 
OSTEOARTHRITIS IN THE DISTAL INTERTARSAL AND TARSOMETATARSAL 
JOINTS OF OLDER HORSES…………………………………………………..…………………………38 
 
4. THE USE OF BIOMARKERS FROM THE TIBIOTARSAL JOINT TO 
DETERMINE SEVERITY OF OSTEOARTHRITIS IN THE DISTAL INTERTARSAL 
AND TARSOMETATARSAL JOINTS OF OLDER HORSES …………..……………………62 
 
5. FUTURE DIRECTIONS…………………………………………………..……..………..………………68 
 
6. FOOT NOTES ………………………………………….……………………………..……………………...72 
 
7. REFERENCES……………………………………………….……………………...…………………….....73 
 
	 	 	 vi		
LIST OF TABLES	
Table	2.1:	Case	horse	signalment	and	reason	for	donation.			yrs=	years;	QH=Quarter	Horse;	Old=Oldenburg;	Am	Pt=American	Paint;	F=mare;	G=gelded	male;	UNK=unknown;	OA=osteoarthritis	Shaded	=	mild	tibiotarsal	disease;	not	shaded=	moderate	tibiotarsal	disease	based	on	arthroscopic	and	gross	scoring	of	the	TT	joints	(Table	2.4).		
Table	2.2:	Clinical	findings	for	the	limbs	entered	into	the	study	based	on	the	presence	of	radiographic	changes	in	the	tarsus	(limb).				TT=tibiotarsal;	jt=joint;	Circum=circumference;	RH=	right	hind;	LH=left	hind;	RF=right	front;	LF=left	front;	n/a=not	applicable	Shaded	=	mild	 tibiotarsal	disease;	not	shaded=	moderate	 tibiotarsal	disease	based	on	arthroscopic	and	gross	scoring	of	the	TT	joints	(Table	2.4). 	
Table	2.3:	Radiographic	scores	for	tibiotarsal	(TT),	proximal	intertarsal	(PIT),	distal	intertarsal	(DIT),	and	tarsometatarsal	(TMT)	joints	for	the	limb	of	interest.	Values	denoted	with	a	dagger	(†)	represent	direct	communication	between	those	given	joints,	as	determined	via	contrast	injection	in	the	DIT	and/or	TMT	joints.		Shaded	=	mild	tibiotarsal	disease;	not	shaded=	moderate	tibiotarsal	disease	based	on	arthroscopic	and	gross	scoring	of	the	TT	joints	(Table	2.4).		Radiographic	scores	for	each	joint	were	graded	for	joint	space	narrowing,	soft	tissue	swelling,	subchondral	bone	lucency,	subchondral	bone	sclerosis	0-3	with	0=	none,	1=	mild,	2=	moderate,	3=	severe;	size	of	largest	osteophyte	or	enthesophyte	graded	0-3	with	0=none,	1=1-2,	2=3-4,	3=	>4;	size	of	largest	osteophyte/enthesophyte	were	graded	0-3	with	0=none,	1=small,	2=medium,	3=large;	total	possible	points	=	18		
Table	2.4:	Summary	of	arthroscopic	lesions	and	additional	gross	examination	scores.		Scores	are	arranged	in	ascending	order	based	on	the	total	score.		Shaded	=	mild	tibiotarsal	disease;	not	shaded=	moderate	tibiotarsal	disease	based	on	arthroscopic	and	gross	scoring	of	the	TT	joints.		Synovial	changes=	total	of	scores	for	hyperemia,	petechiation,	increased	synovial	villi,	new	villus	production,	villus	atrophy,	with	each	category	graded	0-3	with	0=	absent,	1=mild,	2=	moderate,	3=	severe	and	synovialized	debris	graded	0-3	with	0=none,	1=	1-2,	2=	3-4,	3=	>4	Adhesion	formation	graded	0-3	with	0=none,	1=	1-2,	2=	3-4,	3=	>4	(combined	in	chart	with	synovial	score)	MTR=	medial	trochlear	ridge	of	talus;	focal	lesions	graded	0-5	with	0=	none,	1=	1,	2=2,	3=3,	4=4,	5=>4	MTR	lesion	length	graded	0-3	based	on	proximal	to	distal	length	of	lesion	compared	to	entire	trochlear	ridge	with	0=	lesion	<1cm	in	length	of	MTR,	1=	lesion	>1cm	to	
	 	 	 vii		
1/3	in	length	of	MTR,	2=	lesion	1/3	to	2/3	length	of	MTR,	3=	lesion	>	2/3	length	MTR	LTR=	lateral	trochlear	ridge	of	talus;	lesions	and	lesion	length	graded	the	same	as	MTR	lesions	above	Score	lines:	graded	0-4	with	0=none,	1=	1-2,	2=	3=-4,	3=	5-6,	4=	>6	Cart	depth=	cartilage	depth;	the	worst	lesion	was	graded	0-4	with	0=normal,	1=	swelling/softening	of	cartilage,	2=	superficial	fibrillation	of	cartilage,	3=	deep	fibrillation	of	cartilage,	4=	exposure	to	subchondral	bone	Total	possible	points	for	arthroscopic	score	=	45		
Table	2.5:	Additional	lesions	identified	on	gross	examination	in	the	tibiotarsal	joint.	MTR=	medial	trochlear	ridge	of	talus;	LTR=	lateral	trochlear	ridge	of	talus;	MM=	medial	malleolus	of	tibia;	DIRT=	distal	intermediate	ridge	of	the	tibia;	ITG=	intertrochlear	groove			shaded=	mild	combined	arthroscopy	and	gross	score;	no	shading=	moderate	combined	arthroscopy	and	gross	score		
Table	2.6:		Direct	Biomarker	results	ordered	by	tibiotarsal	(TT)	joint	disease	severity	from	Table	2.4.		Mild=	mild;	arthroscopy	and	gross	scores	combined	=	≤	15	points	Mod=	moderate;	arthroscopy	and	gross	scores	combined=	>	15	points	Italicized	number=	half	of	the	lowest	standard	concentration	of	the	biomarker	for	concentrations	that	read	below	the	lowest	standard		Shaded	=	mild	TT	disease;	Not	shaded=	moderate	TT	disease		
Table	2.7.	Indirect	Biomarker	results	ordered	by	tibiotarsal	(TT)	joint	disease	severity	from	Table	2.4.		Mild=	mild;	arthroscopy	and	gross	scores	combined	=	≤	15	points	Mod=	moderate;	arthroscopy	and	gross	scores	combined=	>	15	points	Italicized	number=	half	of	the	lowest	standard	concentration	of	the	biomarker	for	concentrations	that	read	below	the	lowest	standard		Shaded	=	mild	TT	disease;	Not	shaded=	moderate	TT	disease		
Table	2.8.		Biomarker	results	in	the	tibiotarsal	joint.	
 
Table 3.1: Radiographic scores for distal intertarsal (DIT) and tarsometatarsal (TMT) 
joints of limb of interest for each horse. Details of the grading scheme are available in 
Table 2.3   
 
Table 3.2: MRI scores for distal intertarsal (DIT) and tarsometatarsal (TMT) joints of 
limb of interest for each horse.    
 
	 	 	 viii		
Joint effusion, synovial proliferation, subchondral bone hypointenisty (SCB sclerosis), 
and subchondral bone hyperintensity were each graded 0-3 with 0=none, 1= mild, 2= 
moderate, 3= severe.  Cartilage destruction was graded 0-3 with 0=none, 1=mild/ not full 
thickness, 2= moderate/ full thickness with limited extension, 3= severe/ full thickness 
with severe extension.  The number of periarticular osteophytes was graded 0-3 with 0= 
no osteophytes, 1= 1-2 osteophytes, 2= 3-4 osteophytes, and 3= greater than 4 
osteophytes.  The largest osteophyte was graded 0-3 with 0= none present, 1= small, 2= 
medium, 3= large.  All scores were added for each joint to obtain an overall score, with a 
maximum score of 21.  
 
Table 3.3: Distal intertarsal (DIT) joint MRI subcategories split into mild (<7) and 
moderate/severe (≥7) OA groups based on the overall MRI score (Table 3.2).  
Subcategories with significant differences between mild and moderate/severe groups OA 
are denoted by an asterisk.  The mild OA horses are not shaded.  The moderate/severe 
OA horses are shaded.  Grading scheme described in Table 3.2. 
 
Table 3.4: Tarsometatarsal (TMT) joint MRI subcategories split into mild (<7) and 
moderate/severe (≥7) OA groups	based on the overall MRI score (Table 3.2).  
Subcategories with significant differences between mild and moderate/severe groups are 
denoted by an asterisk.  The mild OA horses are not shaded.  The moderate/severe OA 
horses are shaded. Grading scheme described in Table 3.2. 
 
Table 3.5: Distal intertarsal (DIT) joint biomarker concentrations and dilutions used.   
 
Table 3.6: Tarsometatarsal (TMT) joint biomarker concentrations and dilutions used. 
 
Table 3.7: Distal joint biomarker correlations to other biomarkers. 
 
Table 4.1: Radiographic and MRI scores of the proximal intertarsal (PIT) joints. 
 
Table 4.2: Correlations of proximal and distal joint biomarker values. 
 
 
 
 
 
 
 
  
	 	 	 ix		
LIST OF FIGURES 
Figure 1.1: Composition of the extracellular matrix (ECM) in cartilage.  
Figure 1.2:  Chondrocyte and collagen fibril patterns in different layers of articular 
cartilage. 
 
Figure 1.3:  Diagram of an aggrecan molecule (G=globular; HA=hyaluronic acid). 
Figure 1.4: Lateromedial radiograph demonstrating the joints of the equine tarsus. 
Figure 2.1: Photographs showing synovial fossae variations on the intertrochlear groove 
of the talus.  
 
Figure A: Proximal and distal synovial fossae of the intertrochlear groove of the talus. 
 
Figure B: Connection of the proximal and distal synovial fossae (arrows) 
 
Figure 2.2: Representative arthroscopic images of tibiotarsal joint lesions.  Images are 
oriented so distal is at top. 
 
Figure A: Synovial hyperplasia and new rice body formation 
 
Figure B: Superficial cartilage dimpling and fibrillation on distal medial trochlear ridge 
of the talus 
 
Figure C: Superficial cartilage fibrillation on mid aspect of lateral trochlear ridge of the 
talus 
 
Figure D: Full thickness cartilage lesion >1cm on axial surface of the medial trochlear 
ridge of the talus (arrows). 
 
Figure 2.3: Representative tibiotarsal joint lesions observed on gross examination that 
could not be seen arthroscopically.  Images are oriented so proximal is at top. 
 
Figure A: Cartilage lesion present on cochlea of distal tibia (small arrow) surrounding the 
synovial fossa (large arrow); deep score lines present on the proximoaxial aspects of 
medial and lateral trochlear ridges of the talus (arrow heads).   
 
Figure B: Cartilage lesion on plantarolateral aspect on the cochlea of the distal tibia 
(small arrows); variation of synovial fossae on the cochlea of the distal tibia (large 
arrow). 
 
Figure C: Cartilage lesions on the dorsal (large arrow) and plantar (small arrow) aspects 
of the cochlea of the distal tibia.  
 
	 	 	 x		
Figure D: Cartilage lesions on the plantar (small arrow) and plantarolateral (large arrow) 
aspects of the cochlea of the distal tibia. 
 
Figure 2.4: Box and whisker plots comparing direct biomarker concentrations of the 
control group (when applicable), and mild and moderate disease subgroups.  Open 
triangle denotes horse 6 who had direct communication between all tarsal joints 
examined. Open circles represent values that are half of the lowest standard 
concentrations. 
 
Figure 2.5: Box and whisker plots comparing indirect biomarker concentrations of the 
control group (when applicable), and mild and moderate disease subgroups.  Open 
triangle denotes horse 6 who had direct communication between all tarsal joints 
examined.  Open circles and squares represent values that are half of the lowest standard 
concentrations. 
 
Figure 3.1: Preliminary MRI Study – scans from pilot cadaver tarsi 
Figure A: Sagittal proton density weighted image of distal tarsus with OA.  Arrows 
indicate hypointense (black) areas along dorsal aspect of central tarsal and 3rd tarsal 
bones - consistent with sclerosis.  
Figure B: Sagittal T2 weighted, fat saturated image of the distal tarsus with OA.  Arrow 
indicates small area of osseous hyperintensity along the distal border of the central tarsal 
bone dorsally.   
Figure C: Sagittal 3D FSPGR, fat saturated image of distal tarsus with OA.  Large arrow 
indicates cartilaginous defect in dorsal aspect of TMT joint.  Small arrow indicates large 
osteophyte off the dorsal aspect of the third tarsal bone. 
Figure D: Sagittal, color-coded T2 map of distal aspect of normal tarsus.  Cartilages of all 
the small tarsal joints are prominently blue (normal).  
Figure E: Sagittal, color-coded T2 map of the distal tarsus with OA.  Cartilage in blue is 
normal.  Cartilage of DIT and TMT joints are green, compatible with OA lesions.  The 
arrow indicates an area of high increased T2, compatible with a small cartilaginous 
defect. 
Figure 3.2:  Radiographic and MR images from the same horse (horse 8) 
Figure A: Radiographic lateromedial view of the tarsus.  Arrows indicate subchondral 
bone sclerosis identified on the dorsal aspects of the central tarsal and third tarsal bones.   
Figure B: Sagittal proton density weighted MRI of the tarsus. Arrows indicate 
subchondral bone sclerosis identified on the dorsal aspects of the central tarsal and third 
tarsal bones.  The degree of subchondral bone sclerosis is easier to identify on MRI 
compared to radiographic image.   
Figure C: Sagittal, color-coded T2 map of the distal tarsus with OA.  Cartilage in blue is 
	 	 	 xi		
normal.  Cartilage of distal intertarsal (DIT) and tarsometatarsal (TMT) joints are green, 
compatible with OA lesions.  
Figure 3.3: Examples of lesions identified on MRI.  
Figure A:  Sagittal 3D FSPGR, fat saturated MR images of distal tarsus from horse 3. 
Arrow represents severe cartilaginous defect in the dorsal aspect of the tarsometatarsal 
(TMT) joint 
Figure B: Sagittal proton density weighted image of distal tarsus from horse 11.  Arrows 
represent moderate subchondral bone sclerosis in the proximal intertarsal (PIT) and 
severe subchondral bone sclerosis in the distal intertarsal (DIT) and tarsometatarsal 
(TMT) joints.   
Figure C: T2- weighted Short Tau Inversion Recovery (STIR) image of the distal tarsus 
from horse 4.  Arrows represent subchondral bone hyperintensity - mild on the central 
tarsal bone and severe on the third tarsal bone (arrows).  
Figure 3.4: Distal intertarsal (DIT) joint box and whisker plots.  The lowest and highest 
concentrations are represented by the whiskers.  The median is represented by the line 
inside the box.  The 25th and 75th quartiles are represented by the upper and lower box 
limits.  The mean concentration is represented by +.  Asterisks represent statistically 
significant differences between groups. Mild OA	<	7	overall	MRI	score,	moderate/severe	OA	≥	7	overall	MRI	score.			
 
Figure 3.5: Tarsometatarsal (TMT) joint box and whisker plots.  The lowest and highest 
concentrations are represented by the whiskers.  The median is represented by the line 
inside the box.  The 25th and 75th quartiles are represented by the upper and lower box 
limits.  The mean concentration is represented by +.  Asterisks represent statistically 
significant differences between groups. Mild OA < 7 overall MRI score, moderate/severe 
OA ≥ 7 overall MRI score.   	
Figure 4.1: Box and whisker plots of tibiotarsal (TT) SF direct biomarker values split 
into distal intertarsal (DIT) groups based on MRI.  The lowest and highest concentrations 
are represented by the whiskers.  The median concentration is represented by the line 
inside the box.  The 25th and 75th quartiles are represented by the upper and lower box 
limits.  The mean concentration is represented by a +.  Asterisks represent statistically 
significant differences between groups.  Mild OA < 7 overall MRI score, moderate/severe 
OA ≥ 7 overall MRI score. 
 
Figure 4.2: Box and whisker plots of tibiotarsal (TT) SF indirect biomarker values split 
into distal intertarsal (DIT) groups based on MRI.  The lowest and highest concentrations 
are represented by the whiskers.  The median concentration is represented by the line 
inside the box.  The 25th and 75th quartiles are represented by the upper and lower box 
limits.  The mean concentration is represented by a +.  Asterisks represent statistically 
significant differences between groups.  Mild OA < 7 overall MRI score, moderate/severe 
OA ≥ 7 overall MRI score. 
	 	 	 xii		
 
Figure 4.3: Box and whisker plots of tibiotarsal (TT) SF direct biomarker values split 
into tarsometatarsal (TMT) groups based on MRI.  The lowest and highest concentrations 
are represented by the whiskers.  The median concentration is represented by the line 
inside the box.  The 25th and 75th quartiles are represented by the upper and lower box 
limits.  The mean concentration is represented by a +.  Asterisks represent statistically 
significant differences between groups.  Mild OA < 7 overall MRI score, moderate/severe 
OA ≥ 7 overall MRI score. 
	
Figure	4.4:	Box	and	whisker	plots	of	tibiotarsal	(TT)	SF	indirect	biomarker	values	split	into	tarsometatarsal	(TMT)	groups	based	on	MRI.		The	lowest	and	highest	concentrations	are	represented	by	the	whiskers.		The	median	concentration	is	represented	by	the	line	inside	the	box.		The	25th	and	75th	quartiles	are	represented	by	the	upper	and	lower	box	limits.		The	mean	concentration	is	represented	by	a	+.		Asterisks	represent	statistically	significant	differences	between	groups.		Mild	OA	<	7	overall	MRI	score,	moderate/severe	OA	≥	7	overall	MRI	score.	
 
	 	 	 1		
CHAPTER 1: 
PRELIMINARY LITERATURE REVIEW 
 
NORMAL EQUINE JOINT ANATOMY AND PHYSIOLOGY 
 A synovial joint consists of several components including: bone, ligaments, 
muscles, articular cartilage, joint capsule, and synovial fluid [1]. Proper function of these 
joint components is essential to create frictionless contact to allow pain-free mobility.  
Synovial joints are classified into three categories: synarthritic, amphiarthritic, and 
diarthritic.  Synarthritic joints are non-mobile, amphiarthritic joints are slightly mobile, 
and diarthritic joints are mobile and the most numerous type in the body [2]. 
 
THE JOINT CAPSULE 
 The joint capsule is a bilayer structure surrounding the perimeter of each synovial 
joint.  It consists of an outer fibrous layer and an inner synovial membrane.  The outer 
layer provides support to the joint and the inner layer is secretory in nature. The inner 
synovial membrane is a bilayer coating arranged in a villous pattern for enhanced surface 
area and has direct contact with the synovial fluid.  The coating consists of the intimal 
and subintimal layers [2].  
The intimal layer of the synovial membrane is the thin inner layer that consists of 
one to four cell layers.  It determines the make-up of synovial fluid within a joint by 
selective permeability, allowing the passage of small protein molecules less than 10 kDa, 
oxygen, carbon dioxide, and glucose [2]. The intimal layer has specialized cells termed 
synoviocytes.  The three main types of synoviocytes are A, B, and C [2].  Type A 
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synoviocytes are macrophagic and regulate catabolic and anabolic processes through 
phagocytosis. Type B synoviocytes are fibroblastic and regulate protein secretion.  They 
have abundant rough endoplasmic reticulum and dendritic processes that create a network 
within the cell membrane. Type B synoviocytes synthesize and secrete boundary 
lubricants, molecules that provide a coating on the synovial membrane that are dispersed 
into the synovial fluid and prevent joint surfaces from adhering together.  Type C 
synoviocytes are cells that are transitioning from type A to type B [3].  
The main boundary lubricant in synovial fluid is lubricin, made by type B 
synoviocytes.  Lubricin is a 227 kDa O-linked mucinous glycoprotein that is the most 
potent boundary lubricant that is highly preserved across species. [4] It can reduce 
friction in cartilage up to 70 percent [5].  Lubricin is also produced by chondrocytes at 
the superficial and intermediate zone of articular cartilage (see below in articular cartilage 
section), as well as on the surface of the meniscus [6; 7].  
Lubricin creates a brush like structure on cartilage surfaces.  As cartilage is 
compressed through movement, lubricin molecules repel each other and create a 
frictionless surface [4].  Lubricin works in concert with hyaluronic acid (HA), present in 
the synovial fluid and articular cartilage.  Type B synoviocytes also produce HA.  It is a 
high molecular weight linear polysaccharide composed of D-glucuronic acid and N-
acetylglucosamine.  In the synovial fluid, HA is largely responsible for its viscoelastic 
and low shear rate characteristic [8].  HA allows lubricin to lubricate the joint surface at 
high pressures [4], and regulates the transport of substances by creating a diffusion 
barrier by steric hindrance. In the articular cartilage, HA links with aggrecan molecules to 
create osmotic pressure that resists joint compression [8].  
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Between the intimal layer of the synovial membrane and the fibrous joint capsule 
is the subintimal layer.  This layer has an areolar arrangement and is composed of 
collagen, and adipose tissue.  This layout allows the synovial villi to freely move [2].  In 
contrast to the intimal layer, the subintimal layer is highly vascularized and innervated.  
The veins and arteries within the subintimal layer anastomose with the vascular supply of 
the nearby periarticular bone [9].  
 
ARTICULAR CARTILAGE 
 Articular cartilage is specialized connective tissue that lines weight-bearing 
surfaces of the subchondral bones that surround each joint.  The function of articular 
cartilage is to provide a smooth surface with a low coefficient of friction, allowing 
smooth motion during loaded movement of the body [10].  Fluid movement is extremely 
important in maintaining a healthy joint because the motion between cartilage and 
synovial fluid aids in cell nutrition and molecular diffusion [11].  Articular cartilage is 
made up of 1) specialized cells called chondrocytes that produce the extracellular matrix 
and 2) extracellular matrix (ECM) containing mostly water, collagen, and proteoglycans, 
with minimal amounts of noncollagenous proteins, and glycoproteins. There is no 
vascular, neural, or lymphatic supply to the articular cartilage [10].  
Chondrocytes make up 2% of the articular cartilage volume [12].  Each cell has 
its own microenvironment and creates individual extracellular matrices, preventing direct 
signal transduction [10]. Chondrocytes respond to hydrostatic pressure, growth factors, 
and mechanical loads placed upon them [13].   They have non-motile primary cilia that 
sense mechanical load [9].  In horses, the primary cilia were investigated in the weight 
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bearing lateral femoral condyle and the cranial non-weight bearing aspect of the condyle.  
The study found that the primary cilia were organized in areas of high weight bearing 
cartilage and disorganized in non-weight bearing cartilage, suggesting an important role 
in mechanoreception and subsequent chondrocyte metabolism [14].  Chondrocytes 
require specific microenvironments to survive and have limited ability to replicate after 
injury [1].  	The extracellular matrix is 80% fluid and 20% dry matter. The breakdown of 
these components is available in Figure 1.1 Water makes up 80% of the total volume.  
The dry component of the extracellular matrix is predominately collagen.  While several 
types of collagen are present within the extracellular matrix (types I, II, IV, V, VI, IX, 
XI), type II makes up the majority, comprising up to 95% of the collagen fibrils and 
fibers [10].  Collagen creates a scaffold around which the proteoglycans are arranged in 
the articular cartilage and gives it high tensile strength [15]. Collagen also helps keep the 
form of articular cartilage by resisting the pressure placed upon the matrix as water is 
aggregated to the negatively charge glycosaminoglycans [16]. Each collagen molecule is 
composed of 3 identical alpha chains that are wound into a triple helix.  Several helices 
combine into a quarter staggered array formation to create the collagen fibrils [17].  
The extracellular matrix is classified into three zones: pericellular, territorial, and 
interterritorial [10].  The pericellular zone is the part of the extracellular matrix that 
surrounds the chondrocytes and is composed primarily of proteoglycans.  The territorial 
matrix encompasses the pericellular matrix and creates a woven network of collagen 
fibrils that surround and protect the chondrocytes.  The interterritorial region is composed 
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of large collagen fibrils arranged in different orientations related to the joint surface 
depending on the zone of the articular cartilage (Figure 1.2) [10]. 
Articular cartilage is made up of largely non-calcified components with a small 
area that is calcified.  There are four zones of articular cartilage (Figure 1.2): the 
superficial/ tangential zone, the intermediate/transitional/middle zone, the deep/ radiate 
zone, and the calcified zone [2]. The superficial zone represents 10-20% of the articular 
cartilage and has the largest number of chondrocytes with the collagen fibrils oriented 
parallel to the joint surface and being the narrowest in diameter at this location [18].  This 
layer protects the underlying layers from compressive, sheer, and tensile forces induced 
by movement and bearing weight.  The integrity of this layer is crucial to the health of the 
deeper layers [10]. The intermediate zone represents 40-60% of the articular cartilage and 
the chondrocytes in this zone are larger and more oval in shape [10]. The collagen fibrils 
are loosely arranged in this zone and have an increased diameter compared to the 
superficial zone and also help absorb forces of compression [10].  The deep zone 
represents 30% of the articular cartilage and contains the largest chondrocytes [10].  The 
collagen fibers are oriented perpendicular to the joint surface and have the greatest 
resistance to compressive forces of all the layers. [10].  Under the deep zone is a layer of 
calcified cartilage.  The calcified cartilage is the interface between the articular cartilage 
and underlying subchondral bone.  This layer helps attach the collagen to the subchondral 
bone [10].  The junction of the non-mineralized and mineralized portions of cartilage can 
be identified histopathologically and is known as the “tidemark” region [19].  As animals 
age, blood vessels from the subchondral bone can infiltrate into to calcified cartilage [20]. 
Proteoglycans are the second most abundant dry matter molecules present within the 
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extracellular matrix, comprising up to 15% of the total dry matter weight (Figure 1.1).  
Proteoglycans are protein monomers consisting of a core protein with glycosaminoglycan 
side chains attached by covalent bonds.  They are categorized as aggregating and non-
aggregating molecules.  The most common proteoglycans in articular cartilage are 
aggrecan, decorin, biglycan, and fibromodulin [10].  
Aggrecan is the most prevalent and largest aggregating proteoglycan in articular 
cartilage [2]. Each core protein of an aggrecan molecule consists of over 100 side chains 
of the following glycosaminoglycans (GAGs): chondroitin-4 sulfate, chondroitin-6 
sulfate, and keratan sulfate (Figure 1.3).  The chondroitin sulfates attach at the carboxy 
end of the aggrecan molecule and keratan sulfate attaches to the N- terminus, creating 
chondroitin rich and keratan rich areas.  	The aggrecan molecule is separated into three 
globular domains: G1, G2, and G3 (Figure 1.3).  The G1 region interacts with 
hylauronan, the G2 region is on the N- terminal side at the location of keratan sulfate 
aggregation, and the G3 region is on the carboxy side of the molecule [2].	
The function of aggrecan is to help a joint withstand load by binding to HA via a 
link protein (Figure 1.3). The aggrecan core proteins accumulate on the HA molecule, 
which arrange in close proximity.  The negative charges of the GAGs attract water into 
the intrafibrillar space, while simultaneously repelling each other [2].  This interaction 
allows the cartilage to withstand compressive forces during movement [10].   
    
JOINT STABILITY 
Joint stability is defined as “the ability of a joint to maintain an appropriate 
functional position throughout its range of motion” [21]. Stability is provided to the joint 
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by surrounding ligamentous, tendinous, and osseous structures. Ligaments are fibrous 
structures connecting bone to other bones.  In horses, most diarthritic joints in the limbs 
are surrounded by collateral ligaments that provide medial and lateral stability.  
Ligaments are mostly composed of type I collagen fibrils arranged parallel to the 
longitudinal axis of the joint capsule they surround and they have a high elastin to 
collagen ratio, allowing the structure to stretch under normal movement [22].  
Tendons are attachments between muscle and bone.  Tendons are also mainly 
composed of type I collagen fibrils in a proteoglycan matrix [22]. Joints in the proximal 
equine limb rely heavily on tendinous and muscular stability [2].  
Subchondral and epiphyseal bone provide stability and shape to the cartilage.  
Subchondral bone is defined as the bone just below the articular cartilage.  It is highly 
dynamic in nature and adapts to mechanical forces placed upon it.  The subchondral bone 
has two anatomical parts: the subchondral bone plate and the subchondral trabecular bone 
[23].  The subchondral bone plate is located under the calcified portion of articular 
cartilage.  It is porous in composition and has channels extending into the cartilage.  
Vessels and nerves run through the channels and supply the calcified cartilage [23].  The 
arteries, veins, and nerves are highly susceptible to damage from increasing age and 
compressive forces [23].  The channels are abundant in areas of joints where the bone 
plate is thicker and under high mechanical load and more scarce in areas where the bone 
plate is thinner and under less of a mechanical load [24].  The subchondral trabecular 
(cancellous) bone located beneath the subchondral bone plate functions as a shock 
absorber during movement. The cancellous bone is organized into trabeculae that 
	 	 	 8		
organize into a honeycomb appearance and is extremely porous.  This area is highly 
vascularized and innervated [23].   
In conclusion, the diarthritic joint is made up of many components that must work 
in unity to create and maintain a healthy joint environment to allow normal motion.  A 
balance of normal movement biomechanics, catabolic and anabolic processes, and 
selective diffusion are required to maintain a healthy joint environment.  When the 
normal metabolism of the joint is altered, osteoarthritis may develop. 
 
PATHOPHYSIOLOGY OF OSTEOARTHRITIS IN THE EQUINE JOINT 
Osteoarthritis (OA) is a group of diseases of different causes that ultimately lead 
to synovitis, subchondral bone remodeling, and articular cartilage degeneration [1].  The 
origin of osteoarthritis is multifactorial including: synovitis, changes in subchondral 
bone, abnormal biomechanical properties, joint instability, ageing, and metabolic 
disorders [9; 25; 26].  Joint instability occurs when surrounding tissues are damaged from 
either a traumatic event or chronic microdamage from irregular weight bearing, such as 
abnormal conformation.  Simultaneous changes in the articular cartilage, subchondral 
bone, and synovial membrane contribute to the irreversible and perpetuating disease 
process of osteoarthritis.  The effects of osteoarthritis on the synovial membrane, articular 
cartilage, and subchondral bone are outlined below.  
 
CHANGES OF THE SYNOVIAL MEMBRANE IN OSTEOARTHRITIS  
The synovial membrane can be damaged primarily, termed primary synovitis, or 
secondarily, termed secondary synovitis [2].  Initially, as inflammation occurs within a 
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joint and the cartilage is damaged, there is a buildup of debris within the synovial fluid.  
To clear the debris, more type A (macrophagic) synoviocytes are required.  Keeping up 
with increased production needs, the synovial villi undergo hyperplasia and subsequent 
hypertrophy.  More synovial fluid is synthesized to provide nutrients for the new 
synoviocytes. The combination of these events creates the characteristic synovial joint 
effusion seen in osteoarthritis.  Additionally, the joint is unable to clear some of the 
debris and it becomes embedded within the synovial membrane, creating additional areas 
of local synovitis [27].   
As OA progresses, the permeability of the synovial membrane is altered, allowing 
larger molecules to traverse the membrane.   Lubricin and hyaluronan exit more readily 
across the membrane [28].  The synovial fluid composition becomes higher in water 
content, decreasing its viscosity [29].  In osteoarthritis, lubricin levels are decreased from 
reduced expression in type B synoviocytes and chondrocytes in the superficial zone, 
causing a subsequent increase in friction between cartilages surfaces [5].  As the joint 
experiences an increase in friction, articular cartilage becomes damaged and undergoes 
degradation, leading to further cartilage damage, subchondral bone sclerosis, and 
osteophyte formation [30].  In horses with osteoarthritis, it has been shown that there is a 
reduced sialation of lubricin that may decrease its boundary lubricating capability [31]. 
Once the synovial membrane is damaged, it heals with fibrous tissue.  The fibrous 
tissue has decreased elasticity compared to healthy tissue and creates limited range of 
motion to the joint.  Limited range of motion is followed by atypical biomechanics, 
causing abnormal loading to the joint, and the disease process is perpetuated.  The fibrous 
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tissue also has altered permeability, adding to the amount of abnormal debris trapped 
within a joint, and the cycle repeats [2].  
 
CHANGES OF ARTICULAR CARTILAGE IN OSTEOARTHRITIS  
After the process of osteoarthritis has been incited within a joint, inflammation 
occurs and causes changes within the joint environment. Cartilage changes start at areas 
of increased sheer stress, that could be induced primarily, or may occur secondary to 
changes in the underlying subchondral bone [32]. Chondrocytes alter their metabolism in 
response to the changes in the surrounding environment and become active [9].  
Chondrocytes have limited ability to regenerate and the activation of them can lead to 
changes in the ECM and increased maturation and calcification of the calcified zone [9].  
An increase in vascularity of the calcified cartilage from subchondral bone vessels is 
observed [1]. The vascular channels also have nerves that can be a nidus for pain [33]. 
As chondrocytes detect environmental change, they are stimulated to release 
regulatory proteins termed cytokines. Cytokines are classified as anabolic, modulatory, or 
catabolic [34]. Anabolic cytokines are up-regulated in early OA then down-regulated in 
late stage OA [35]. Major anabolic cytokines include insulin-like growth factor (IGF) and 
transforming growth factor (TGF).  These cytokines stimulate the production of 
chondrocytes, proteoglycans, and type II collagen [2].  Modulatory cytokines, such as IL-
6 can be both pro- or anti-inflammatory by up-regulating other anabolic or catabolic 
cytokines [36]. Major catabolic cytokines produced in response to osteoarthritis are 
interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNFα) [37].  When IL-1 and 
TNFα are increased, there is an up-regulation and production of matrix 
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metalloproteinases (MMPs), aggrecanases, nitric oxide (NO); and a down-regulation of 
synthesis of aggrecan, type II collagen, and MMP inhibitors [2; 9]. Chondrocytes also 
release specific cytokines called chemokines.  Chemokines act as attracting agents for 
inflammatory cells.  Examples of chemokines released by chondrocytes are IL-8 and 
CXCR-3, 4, 5, and 6 [9].  When inflammation occurs in a joint, the chemokines can be 
up-regulated in an exaggerated manner and provoke further inflammation [38].   
MMPs are enzymes that are capable of degrading components of the extracellular 
matrix.  They require zinc for binding sites to be active and are named both by numerical 
standards and by the substrate they degrade [2].  The main MMPs seen with osteoarthritis 
are: MMP-1 (collagenase 1), MMP-8 (collagenase 2), MMP-13 (collagenase 3), MMP-2 
(gelatinase A), MMP-9 (gelatinase B), and MMP-3 (stromelysin 1).  The three 
collagenases cleave the type II collagen triple helix into 1/4 and 3/4 length fragments, 
with MMP-1 being the most predominant [16]. . MMP-8 is usually only present in times 
of great inflammation or sepsis as it is released from neutrophils. MMP-13 (up-regulated 
by IL-1 and TNF) is the most potent collagenase as it cleaves type II collagen 10 times as 
quickly as MMP-1 [2]. Gelatinases degrade collagen by unwinding the triple helix 
formation after cleavage and stromelysins break down proteoglycans and collagen. [1; 2; 
9].  As the cartilage matrix is degraded, there is an increase in water content in the 
extracellular matrix that makes the joint less effective at withstanding loads [16].   In 
addition, when cartilage is injured, damage-associated molecular patterns (DAMPs) 
attach to Toll-like receptors (TLR) on chondrocytes.  The expression of TLRs in 
chondrocytes increases in joints with OA [39].  Up-regulation of TLRs (specifically TLR 
2 and TLR 4) cause an increased expression of MMPs and NO [9].  Other enzymes that 
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contribute to cartilage breakdown include: a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) [2].  ADAMTS enzymes are also called 
aggrecanases and they break down and deplete the proteoglycan core protein.  There are 
natural inhibitors of MMPs and aggrecanases, called tissue inhibitors of 
metalloproteinases (TIMPs) that bind to MMPs and aggrecanases, making them inactive 
[2].   
 
CHANGES OF SUBCHONDRAL BONE IN OSTEOARTHRITIS  
There is evidence that suggests initial changes in OA occur in the subchondral 
bone [32; 40-42].  The subchondral bone is traumatized either by an injury or chronic 
microdamage.  As the bone remodels, the subchondral bone plate thickens.  The changes 
in thickness between normal and abnormal bone cause irregular shear forces on the joint.  
The adjacent subchondral bone spongiosa is subjected to the abnormal forces and 
experiences inflammation, bone edema, and bone marrow necrosis [43].  The appearance 
of the changes in the spongiosa and bone marrow can be visualized on MRI using T2 fat 
suppressed images and are consistent with early OA [43].  The articular cartilage can also 
experience abnormal shear forces from changes of the subchondral bone plate that result 
in areas of fibrillation [32].  It is also hypothesized that forces placed upon the 
subchondral bone cause sclerosis at weight bearing areas causing the tidemark region to 
thicken and the articular cartilage to thin [32]. The cartilage eventually ossifies at the 
articular margins, leading to osteophyte formation [29]. Conversely, as the cartilage 
erodes subchondral bone is eventually exposed.  Loading the subchondral bone without 
the protection of the articular cartilage causes it to undergo eburnation and become 
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thickened. The subchondral bone also undergoes lysis and can have cystic formation 
from chronic bone-to-bone contact and synovial fluid invasion [32].   
 
CLINICAL MANIFESTATION OF OSTEOARTHRITIS IN THE TARSUS OF THE 
EQUINE ATHLETE 
The equine tarsus consists of five joints: tibiotarsal, talocalcaneal, proximal 
intertarsal, distal intertarsal, and tarsometatarsal (Figure 1.4).  OA commonly develops in 
the distal intertarsal (DIT) and tarsometatarsal (TMT) joints of performance horses 
(collectively termed “the distal tarsal joints”).  OA in the distal tarsal joints is one of the 
most common causes of pelvic limb lameness in performance horses [44].  Proximal 
intertarsal (PIT) OA is rare, and it can be associated with DIT and TMT OA with clinical 
signs often manifesting in the tibiotarsal (TT) joint [45; 46].  OA of the TT joint is less 
commonly reported than in the distal joints, but may be under reported because OA is 
often not visible on radiographs.  
Currently, the most accurate method of identifying OA in the distal tarsal joints is 
the combination of thorough physical, lameness, and radiographic examinations [47-49]. 
Physical examination often relies on conformation assessment, presence of a positive 
Churchill test (the application of digital pressure on the distal intertarsal joint and 
assessing pain response), combined with bilateral hind limb lameness, and positive 
response to upper limb flexion [47]. Intra-articular anesthesia can be administered to help 
localize lameness.  Radiography is the most commonly used imaging modality but 
lameness often does not correlate with radiographic changes; several studies have noted 
both severe radiographic changes with mild lameness in horses, or very little radiographic 
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changes with severe lameness [48-54].  Radiographic evidence of OA (narrowed joint 
space, sclerotic bone, osteophytes, and bony bridging) takes time to develop, which is 
likely why radiographic findings are highly variable compared to clinical findings and the 
degree of lameness.  For example, up to a 50% decrease in bone density can occur before 
changes are visualized on radiographs [55].  Additionally, radiology gives little 
information about cartilage and soft tissue integrity [48].  
In the TT joint, primary OA usually presents as effusion and lameness that 
responds to flexion with no detectable radiographic abnormalities [45; 46; 56]; many 
aged horses have this clinical presentation that is usually complicated by radiographic 
OA in the distal joints. It has even been pointed out that radiographs could not identify 
subchondral cysts in TT joints due to summation of opacities and overlapping contours 
[57; 58].  Because of the lack of radiographic findings in TT joints and presence of distal 
joint changes, the distal joints are often treated, while the TT joint effusion is ignored.  It 
is not clear how the disease in the distal joints affects the TT joint, or whether OA is 
under-diagnosed in TT joints of older horses.  
Diagnosing OA in the tarsal joints in horses presents a clinical challenge because 
readily attainable and reliable diagnostics are not available.  Arthroscopic surgery is the 
gold standard for evaluating the TT joint [45; 46].  Arthroscopy allows direct 
visualization of the articular cartilage and joint environment.  Inflammation can be 
visualized by the presence of hyperemia, thickened synovial villi, new villi formation, 
and villus atrophy.  Lesions can be categorized based on size and number, presence of a 
kissing lesion, and extent of cartilage damage [59].  However, arthroscopy provides little 
information about the underlying subchondral bone.  Additionally, arthroscopy is a 
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surgical procedure requiring general anesthesia, a known risk factor in aged horses [60], 
while potentially being cost prohibitive.  
In the distal tarsal joints, arthroscopy is not an option.  The small size of these 
joints prevents the use of this diagnostic tool.  Since direct visualization of the distal 
tarsal joints is not possible, Magnetic Resonance Imaging (MRI) is considered the gold 
standard for evaluating them. MRI is a superior imaging modality in identifying specific 
anatomic lesions affecting cartilage, subchondral bone, synovium and surrounding soft 
tissues when compared to radiology, ultrasonography, and nuclear scintigraphy [61-64].  
An important finding visualized on MRI and not radiographs is subchondral bone 
hyperintensity.  As bone marrow necrosis and bone edema forms in early OA, the 
changes in the spongiosa and marrow of the bone cause a hyperintense area to appear on 
T2 weighted fat suppressed MRI [63].  In humans, it has been noted that SCB 
hyperintensity viewed on T2 STIR images could be indicative of reactive sclerosis with 
newly formed fibrovascular tissue, versus mature sclerosis that often appears hypointense 
[65].  If horses act in a similar manner, identification of SCB hyperintensity could be a 
good indicator of early and active disease since it has been stated that SCB hyperintensity 
of the distal tarsal joints may correlate with clinical lameness [63].   
Unfortunately, MRI of the tarsus in a live horse in a high field magnet is often 
unattainable due to financial limitations, anatomical restraints of fitting the leg into 
magnets with smaller bores, and the need for general anesthesia.  The lack of a diagnostic 
tool able to not only determine the presence of OA in the distal hock joints but to also 
track disease progression and response to treatment, often leads to over-treatment of these 
joints.  In fact, it is common clinical practice to inject the distal tarsal joints of horses 
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with intra-articular corticosteroids up to every 6 months throughout horses’ careers even 
though there is plenty of suggestion in the literature that corticosteroid treatment into a 
joint is not benign [66-68].  Therefore, there is an urgent need for minimally invasive, 
reliable, quantitative diagnostic test in horses that can detect early OA in these joints; 
ideally one that can then monitor the progression of OA such that the timing of treatment 
can be appropriately controlled.   
A novel way to detect early OA changes in the joint is through the measurement 
of biomarkers from the synovial fluid (SF) from the joint of interest [35].  To the authors’ 
knowledge, there are no studies examining biomarkers from the TT, DIT, and TMT joints 
in an aged horse population.  
MOLECULAR BIOMARKERS OF OSTEOARTHRITIS 
There is an urgent need for minimally invasive, reliable, quantitative tests for 
detection of early OA changes in joints.  Molecular biomarkers of OA are some of the 
most minimally invasive tests used at this time. They reflect quantitative and dynamic 
variations associated with joint metabolism [59].  Two basic types of molecular 
biomarkers have been studied: direct and indirect biomarkers. Since the concentrations of 
these biomarkers often drive joint metabolism, they may provide an earlier indication of 
disease status. 
  
 
 
 
 
	 	 	 17		
DIRECT BIOMARKERS: 
Direct biomarkers are a result of changes in joint metabolism [69].  There are 
many commercially available direct biomarkers that have been analyzed in the horse.  
This study will focus on those that represent collagen synthesis: CPIIa; collagen 
degradation: C12Ca, C2Ca, and CTXIIb; aggrecan turnover: CS846a; and osteoblastic 
turnover: BAPc. The premise behind each of these biomarkers is listed below.  
Collagen synthesis is up-regulated in early OA and the carboxy propeptide of type 
II collagen (CPII) is an epitope of protein fragments released during collagen formation.   
After the procollagen molecule is released by a chondrocyte, the carboxy-propeptide is 
cleaved and the collagen molecule joins the fibril.  The cleaved portion of the 
procollagen, CPII, can be measured in synovial fluid [17; 70].  In humans, CPII has been 
shown to increase in OA until synthesis cannot keep up with degradation and then 
concentrations decrease [71]. A study in humans demonstrated CPII was able to predict 
future radiographic changes in women with tibiofemoral joint osteoarthritis [17].  This 
could be extremely important clinically in horses, as radiographic changes often lag 
behind the disease process.  In horses with intra-articular fractures, CPII was elevated 
compared to normal horses [72].  Another study in horses demonstrated that CPII is 
affected by age with yearlings having significantly higher concentrations compared to 
adult horses [73].  In horses with OCD lesions on the distal intermediate ridge of the 
tibia, CPII values were not found to be increased compared to non-affected joints [74]. 
C1,2C concentrations represent degradation products of both type I and type II 
collagen by identifying the neoepitope created after collagenase cleavage of the triple 
helix at the ¾ length carboxy (C) terminus region.  The neoepitope created after MMP 
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cleavage is relatively long so it identifies both type I and II collagen [16].  	After the 
triple helix is cleaved, the pieces are released into synovial fluid and can be measured 
[75]. C1,2C has been demonstrated to increase in horses with induced middle carpal joint 
OA compared to horses without OA [76] and in synovial fluid from equine carpal and 
fetlock joints with osteochondral injury, and in yearlings [73].   
C2C also represents collagen degradation by identifying the neoepitope created 
after collagenase cleavage of the triple helix.  The difference is that the neoepitope is 
shorter than that of C1,2C making it more specific to type II collagen [16]  .  After the 
triple helix is cleaved, the pieces are released into synovial fluid and can be measured 
[75]. A specific equine antibody for this neoepitope, 234CEQ, has been described and 
utilized [75] but is not readily available; thus a human assay (C2Ca) has been used by 
most equine researchers.  Studies evaluating C2C concentrations in horses have found 
that concentrations are affected by age and are elevated in joints with OA and OCD.  It 
has been shown that osteochondral injury of Thoroughbred horses increases the 
concentration of C2C in the synovial fluid of carpal and fetlock joints compared to 
uninjured cartilage of rested and exercised horses [77].  One study showed that age, 
presence of osteochondral injury and joint affected all influenced C2C concentrations 
[73]; yearling horses were found to have higher concentrations of C2C compared to 
adults.   In horses with osteochondral injury in the fetlock and carpus, higher C2C 
concentrations were found in the carpus [73].  In horses with OCD lesions on the distal 
intermediate ridge of the tibia, C2C values were not found to be increased compared to 
non-affected joints in one study [74], but were increased compared to normal horses in 
another study [72].   
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Cross-linked C-telopeptide fragments of type II collagen (CTX II) measures 
degradation of type II collagen (close to the bone cartilage interface) via identification of 
a type II collagen C-telopeptide epitope [69].  In horses, CTX II concentrations have been 
shown to increase in horses with OA, and are also affected by age.  Synovial fluid 
concentrations of CTX II in adult horses with osteochondral injury in the middle carpal 
and fetlock joints were significantly higher compared to radiographically normal joints of 
horses before and after exercise [78].  CTX II values were increased in yearlings 
compared to adult horses and in osteochondral injured middle carpal joints compared to 
injured metacarpophalangeal joints [73].  In Standardbred horses with post-traumatic 
osteoarthritis there was an increase in CTX II concentrations over a 4 year time period 
[79].  
The chondroitin sulfate 846 (CS846) epitope is located on the chondroitin sulfate 
side chains near the G3 domain and as such represents newly synthesized aggrecan 
molecules; it is released from the extracellular matrix into the synovial fluid once it is 
cleaved from the aggrecan protein.  These large fetal forms of aggrecan (intact protein 
cores out to G3 domain) are naturally present in young animals, but then decrease in 
cartilage with age. Concentrations increase again in older animals with osteoarthritis 
suggesting that cartilage is undergoing aggrecan core protein turnover more readily when 
pathology is present [80].  In horses, CS846 concentrations were elevated in joints with 
OA compared to those without, and have been used to predict OA in working horses.  In 
polo ponies, CS846 increased during the working season and were significantly higher in 
ponies that later developed osteoarthritis [81].  CS846 was also elevated in the middle 
carpal joints in 2 year old horses with induced OA undergoing exercise [76].   
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Bone alkaline phosphatase (BAP), is an isoenzyme of alkaline phosphatase, which 
is a marker of early osteoblastic activity [82].  It locally increases the concentration of 
extracellular inorganic phosphate, which increases mineral formation and decreases 
extracellular pyrophosphate, a mineral inhibitor [82].  BAP is a biomarker that could 
potentially provide information about the subchondral bone status in joints.  In horses, 
BAP concentrations have been shown to increase in joints with OA and OCD lesions.  In 
a study of racehorses in training, carpal and fetlock joint synovial fluid BAP 
concentration was positively correlated with cartilage damage [83].  In horses with 
osteochondral fragments in the carpus, BAP in synovial fluid was significantly elevated 
[59]. 
INDIRECT BIOMARKERS   
Indirect biomarkers, by definition, indirectly change the metabolism in the joint 
[35]. Commercially available indirect biomarkers that will be focused on in this research 
include cytokines interleukins (IL) -1βd, -6d, -8d, -10d, and tumor necrosis factor alpha 
(TNFαd).  IL-1β and TNFα are catabolic cytokines.  IL-6 is a modulatory cytokine, IL-8 
is a chemokine, and IL-10 is an anti-catabolic cytokine [36]. 
IL-1β is a strong pro-inflammatory cytokine that stimulates cartilage matrix 
degeneration [36].  It was found to be a good identifier of acute severe joint disease, but 
not good as a screening tool for chronic or less severe joint disease in horses with 
naturally occurring OA [84].  In horses, IL-1β concentrations have been shown to elevate 
acutely after joint injury then fluctuate afterwards, and are also affected by age.  In 
Standardbred racehorses with post traumatic OA, IL-1β levels peaked acutely, declined 
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over the first year after injury, than gradually increased again over the following three 
years [79].  Trumble et al [85] identified elevated levels of IL-1β in younger horses with 
OCD lesions.   
TNFα is another pro-inflammatory cytokine that works synergistically with IL-1β 
[86].  Studies evaluating TNFα have demonstrated that this cytokine is beneficial to 
identify severe OA.   A study examining joints of horses with naturally occurring OA 
found that TNFα was a good predictor of acute severe joint disease, but not in chronic 
disease [84].  Another study found TNFα levels elevated in horses with severe OA in 
both acute and chronic cases [87].  A couple of studies have found no correlation between 
macroscopic cartilage damage and SF TNFα concentrations in the joints of horses [88; 
89].  One study identified increased SF concentrations in horses with severe carpal 
fractures but not in horses with smaller OCD fragments [90]  In contrast, another  study 
did find increased SF concentrations of TNFα in horses with OCD lesions and in joints 
after acute joint trauma [85].  The results of these studies indicate that TNFα is 
predominately elevated in acute and severe traumatic OA and in some horses with OCD 
lesions.  
A modulatory cytokine such as IL-6 can be either pro- or anti-inflammatory [91].  
IL-6 has been shown to increase in carpal joints of horses with both induced synovitis 
[92; 93] and in naturally occurring disease [84; 88; 90].  One study had the highest levels 
of IL-6 in horses with carpal osteochondral fragments and synovitis [88].  A single 
sample of IL-6 from an injured joint was found to be an excellent predictor of OA; Il-6 
was not found in any normal joints, suggesting that finding any levels of IL-6 may be 
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relevant [84]. The results of these studies demonstrate that the source of IL-6 could be 
from the synovial cells and/or osteoclasts to induce bone resorption.  
IL-8 is a chemokine and as such recruits neutrophils and stimulate their secretion 
[94].  It has also been shown to stimulate the release of enzymes that degrade the ECM 
[95].  IL-8 is also angiogenic [96].  IL-8 was up-regulated in vitro in equine chondrocytes 
that were stimulated by human recombinant IL-1β [97].  IL-8 may have an important role 
in equine OA.  
IL-10 is an anti-catabolic cytokine.  This cytokine can inhibit cartilage 
degeneration directly and indirectly.  Directly, IL-10 degrades proteinases and decreases 
the synthesis of pro-inflammatory cytokines [36].  Indirectly, IL-10 has been shown to 
increase interleukin-1 receptor antagonist (IL-1ra) concentrations, inhibiting IL-1 [34].   
In horses, IL-10 concentrations have been shown to increase within one week of intra-
articular mesenchymal stem cell injection into fetlock joints [98]. 
 In conclusion, OA is a multifactorial disease with many anatomical structures 
involved.  Biomarkers have been shown to have clinical value in identifying OA.  To the 
author’s knowledge, no study has yet looked at biomarkers in the tarsus specifically in an 
aged horse population.   
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CHAPTER	2:	
CLINICAL CHALLENGE OF DETERMINING OSTEOARTHRITIS IN 
TIBIOTARSAL JOINTS OF OLDER HORSES: USE OF DIRECT AND 
INDIRECT BIOMARKERS TO DETERMINE THE PRESENCE AND 
SEVERITY OF DISEASE 
 
Osteoarthritis (OA) is a multifactorial disease characterized by synovitis, 
subchondral bone remodeling, and articular cartilage degeneration.  In horses, OA 
clinically manifests as lameness [99], with the tarsus being a common location.  The 
distal joints (distal intertarsal [DIT] and tarsometatarsal [TMT]) are the most commonly 
affected, often showing mild to marked radiographic changes of OA.  Proximal intertarsal 
(PIT) OA is rare, and it can be associated with DIT and TMT OA with clinical signs 
often manifesting in the tibiotarsal (TT) joint [45; 46].  Primary OA of the TT joint 
usually presents as effusion and lameness that responds to flexion with no detectable 
radiographic abnormalities [45; 46; 56]; many older horses have this clinical presentation 
that is usually complicated by radiographic OA in the distal joints.  Because of the lack of 
radiographic findings in TT joints and presence of distal joint changes, the distal joints 
are often treated, while the TT joint effusion is ignored.  It is not clear how the disease in 
the distal joints affects the TT joint, or whether OA is under-diagnosed in TT joints of 
older horses. Arthroscopic surgery is the gold standard for OA diagnosis in TT joints [45; 
46] but is rarely performed in older horses with distal tarsal OA.  
Another way to identify the presence of TT joint OA is through measurement of 
molecular biomarkers from synovial fluid (SF). Biomarkers reflect quantitative and 
dynamic variations of joint metabolism, and are classified as direct (result of changes in 
metabolism) or indirect (alters metabolism) [35]. Biomarkers have been successfully used 
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in horses to identify mainly carpal and/or fetlock OA [59; 73; 76-79; 83; 84; 88]. The TT 
joint has been examined using biomarkers, but the focus has been on OCD lesions in 
young horses [72; 74; 100-104]. To the authors’ knowledge, there is only one biomarker 
study within the tarsus that has focused on OA (specific to TMT joint) [105]; no study 
has examined biomarkers in the TT joint from older horses that also have radiographic 
OA in distal tarsal joints.  
The objective of this research was to measure SF biomarker concentrations from 
TT joints of older horses with distal tarsal joint OA to determine if they correlate to 
radiographic, clinical, arthroscopic, and/or gross evidence of OA in the TT, PIT, DIT, 
and/or TMT joints.  We hypothesized that TT OA would be underestimated on 
radiographs and clinical examination compared to arthroscopic and gross findings, and 
that TT joint biomarker concentrations would correlate to TT and PIT pathologic 
findings, but would not be influenced by the presence of DIT and TMT OA.  
 
Materials and methods 
Horses were enrolled from a population of animals donated to the University 
(IACUC Approval #1411-32001A) for educational purposes (Table 2.1). The inclusion 
criterion was radiographic evidence of tarsal OA in any or all of the tarsal joints (TT, 
PIT, DIT, TMT).  Horses with OCD lesions in TT joints were excluded. Radiographic 
changes could range from mild to severe joint space narrowing, soft tissue swelling, 
subchondral bone sclerosis/lucency, and/or presence of osteophytes/enthesophytes.  
Controls were selected from an additional group of 13 horses donated to the University 
(IACUC Approval #1201A08201) that lacked specific musculoskeletal abnormalities.  
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No radiographic, clinical, or arthroscopic data were available for control horses. Control 
horses had TT joint SF collected and processed as described below with a subsequent 
post-mortem gross exam that was documented via digital photographs.  To be included as 
controls, cartilage lesions were graded as described below and had to have a score ≤2.    
For both cases and controls, Phenylbutazone was discontinued 48 hours prior to 
evaluation since it can alter biomarker concentrations [106].  	
Both tarsi of each case horse were radiographed (lateromedial, dorsoplantar, and 
dorsolateral to plantaromedial and dorsomedial to plantarolateral obliques).  The tarsus 
with the most overall radiographic changes was chosen as the limb of interest (Table 2.2), 
and radiographic scores were individually determined for each joint (TT, PIT, DIT, and 
TMT) using a modified scoring system [59] for a total possible score of 18 (Table 2.3).  
Radiographs were scored by a blinded surgeon and radiologist and mean scores were 
recorded.  	 Each case horse received a musculoskeletal examination. Churchill responses, TT 
joint effusion was evaluated and circumferential measurements were performed by the 
same investigator and were scored as listed in Table 2.2. Two blinded surgeons graded 
videotapes of a walk and trot in a straight line (hard surface), and in circles in each 
direction on a soft surface using the AAEP scale [107]. Full limb flexion tests were also 
scored (Table 2.2). Mean scores were recorded.  No attempt was made to isolate the 
cause of lameness.  
Horses were then euthanized and TT joint SF was harvested within 30 minutes.  
Samples were collected from the dorsomedial pouch, and were centrifuged, aliquoted, 
and stored at -80C° until further analyses.  
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Contrast radiography was performed on the limb of interest of case horses to 
determine presence of direct communication between tarsal joints. Three mL of iohexol 
(Omnipaque)e were injected into TMT joints, with needle placement verified by 
radiographs.  A lateromedial radiograph was obtained to assess and record 
communication.  This was repeated for the DIT joint.  
Tibiotarsal joints of each limb of interest in case horses were examined 
arthroscopically using standard dorsal and plantar portals [108].  By modifying a 
published scoring system [59], arthroscopic findings were scored for synovial 
inflammation, adhesion formation, presence of synovialized debris, number, length, and 
depth of non-linear cartilage lesions, and number and depth of linear score lines (Table 
2.4). Scores were summated to yield an overall score that could range from 0-45. 
Tibiotarsal joints were then disarticulated and examined grossly.  Lesions 
identified by arthroscopy were confirmed, and were not given a gross score.  An 
additional gross score was calculated for case horses using the arthroscopic scoring 
system (Table 2.4) to account for lesions that could only be identified after joint 
disarticulation.  The intertrochlear groove (ITG) was only evaluated and scored grossly 
because its entirety could only be evaluated after disarticulation.  If synovial fossae on 
the proximal and distal aspects connected (Figure 2.1), then an ITG score of 1 was 
recorded. For case horses, arthroscopy and additional gross scores were summated to 
derive a total arthroscopy/gross score for TT joint pathology.  Control horses did not have 
any arthroscopic examination but were assigned gross scores based on arthroscopic 
scoring for cartilage lesions (Table 2.4) and ITG gross scoring described above.   
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Tibiotarsal joint SF was analyzed using commercially available ELISAs. For case 
horses, the following direct biomarkers were measured for type II collagen synthesis 
(carboxy-terminal propeptide of type II collagen: CPIIa and degradation (neoepitope 
generated by collagenase cleavage of type II collagen: C2Ca and types I and II collagen: 
C12Ca as well as the C-terminal crosslinked telopeptide of type II collagen: CTX IIb. In 
addition, aggrecan turnover was assessed using the chondroitin sulfate epitope 846: 
CS846a and early osteoblastic turnover was assessed using bone alkaline phosphatase: 
BAPc  Indirect biomarkers examined represented different equine specific cytokines 
including: catabolic (interleukin [IL]-1 beta [IL-1β]dand tumor necrosis factor alpha 
[TNFα]d, modulatory (IL-6)danti-catabolic (IL-10)d and chemokines (IL-8)d  For control 
horses, previously analyzed direct (C2C, CTXII, CPII, CS846, and BAP) and indirect 
(IL-1β, IL-6, and IL-10) biomarkers were available for comparison. Biomarkers were 
analyzed according to manufacturer instructions at appropriate dilutions.  Concentrations 
determined to be less than the lowest standard were assigned a value of ½ the 
concentration of the lowest standard so that samples could be represented graphically and 
statistically. 
Gaussian distribution could not be assumed and no transformation was 
appropriate for all data.  Spearman correlations were used to determine correlations 
amongst all horses (controls and cases) for: age, sum of cartilage arthroscopy and gross 
scores, and biomarker concentrations.  Spearman correlations were also performed on 
cases only for: age, Churchill test, TT joint effusion and circumference, lameness, 
radiographic scores, sum of synovial arthroscopy scores, sum of cartilage arthroscopy 
scores, total arthroscopy score, combined total arthroscopy/gross scores, and biomarker 
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concentrations. Based on total arthroscopic/gross scores, a clear line was evident to 
separate case horses using 15 as the cut-off into subgroups of mild (<15) and moderate 
(≥15) OA severity.  Kruskal-Wallis test with Dunn’s multiple comparisons was used to 
determine differences among control, mild, and moderate OA severity groups for C2C, 
CPII, CS846, CTXII, BAP, IL-1β, IL-6, and IL-10.  Unpaired Mann-Whitney tests were 
used to compare mild and moderate OA severity groups for clinical and radiographic 
findings as well as C12C, IL-8 and TNFα (no control values available). Sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), and 
likelihood ratio of SF C2C concentration to discriminate between presence and absence 
of OA between controls and case horses were determined using a ROC analysis and 
Fisher’s exact test.  P values of ≤0.05 were considered significant using statistical 
softwaref,g. 
 
Results 
Eleven case horses, ranging in age from 9-35 years old (mean=21), and 6 control 
horses, ranging in age from 7-26 years old (mean=16) were included in the study. 
Signalment and clinical findings for case horses are summarized in Table 2.1 and 2.2.  
Radiographic scores for the TT, PIT, DIT, and TMT joints are listed in Table 2.3.  The 
TT joint radiographic scores ranged from normal to mild disease (0-2.5).  Radiographic 
scores for the PIT, DIT, and TMT ranged from normal to severe disease, with DIT 
disease scores being higher than all PIT scores and most TMT scores.  There were no 
significant correlations of TT joint radiographic scores and PIT, DIT, or TMT.  DIT and 
TMT radiographic scores positively correlated (R=0.740; P=0.009). Contrast radiography 
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identified direct communication between DIT and TMT in 4 horses (36%), with one (9%) 
also communicating with PIT and TT joints (Table 2.3).   
Musculoskeletal and lameness examination findings are reported in Table 2.2. 
Effusion scores did not correlate with circumference measurements, but did positively 
correlate with Churchill responses (R=0.800; P=0.003).  There were no other significant 
correlations of clinical parameters to themselves or radiographic scores.  Seven horses 
had baseline lameness in the chosen limb; however, one of these horses (horse 2) had a  
more pronounced forelimb lameness.  Of the 10 horses that were able to trot, 9 were 
positive to full limb flexion of the chosen limb, with most being mild.  Two horses 
(horses 3 and 8) donated specifically for tarsal OA demonstrated baseline lameness 
grades of 2/5, moderate flexion and Churchill responses, and moderate to severe TT joint 
effusion.  
Most of the pathology present within TT joints could be identified via 
arthroscopic examination (Table 2.4 and Figure 2.2). All but one horse had changes 
present in the synovial membrane (Figure 2.2A), with age positively correlating to 
synovial membrane changes (R=0.630; P=0.040).  All horses had cartilage lesions in TT 
joints, with the most common locations on medial (Figure 2.2B), and lateral trochlear 
ridges (Figure 2.2C) of the talus.  Six horses had deep cartilage lesions present, with 
exposure of subchondral bone in 4 (Figure 2.2D).  When linear score lines were present 
(Figure 2.3A), they extended the majority of proximal to distal distance of the trochlear 
ridges.  Arthroscopic synovial and cartilage scores were positively correlated (R=0.640; 
P=0.030).  Additional gross finding scores ranged from 0-8 (Table 2.5).  The cochlea of 
the distal tibia had cartilage lesions present in 7 horses including lesions surrounding the 
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synovial fossa and/or multiple focal lesions or score lines distant from the fossa (Figure 
2.3).  Total arthroscopic/gross scores negatively correlated with DIT radiographic scores 
(R=-0.640; P=0.040), with no other significant correlations with remaining radiographic 
scores or clinical findings. 
 Based on total arthroscopic/gross scores, case horses were divided into two OA 
subgroups for TT joints (Table 2.4): ≤ 15=mild OA (n=6) and >15=moderate OA (n=5).  
For clinical and radiographic findings there were no significant differences between mild 
and moderate severity groups. There were also no significant differences between 
controls and/or mild and moderate severity groups for any direct (Figure 2.4) or indirect 
(Figure 2.5) biomarker concentrations.  Complete data for all biomarkers with all horses 
combined, as well as for each individual horse are summarized in Tables 2.6-2.8.  IL-6 
was the only biomarker to positively correlate to amount of disease identified on 
arthroscopy and/or gross examination when only looking at the case horses (total 
arthroscopy score R=0.683; P=0.020, and combined total arthroscopy/gross scores 
R=0.650; P=0.030).  However, when controls were combined with case horses, C2C and 
IL-6 concentrations both positively correlated with cartilage arthroscopy/gross scores 
(R=0.540; P=0.030 and R=0.530; P=.030, respectively).  Based on ROC analysis, a C2C 
concentration of 187.44 pmol/mL was used to determine predictive value (P=0.03) for 
discriminating OA in the TT joint (OA>187.44), yielding: sensitivity=91%, 
specificity=67%, PPV=83%, NPV=80%, and likelihood ratio=3.  In addition, when all 
horses were combined, age positively correlated with cartilage arthroscopy/gross scores 
(R=0.580; P=0.020), IL-1β (R=0.540; P=0.030), and IL-10 (R=0.570; P=0.030).  In horse 
6 who had direct communication of all joints, indirect biomarker concentrations were 
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elevated compared to other horses (denoted by triangle in Figures 2.4 and 2.5).  All 
cytokines were positively correlated to each other. 
 
Discussion 
Mature horses with evidence of radiographic OA present in distal joints (DIT and 
TMT joints) were enrolled into our study to evaluate whether radiographic changes in 
these joints correlated to biomarker concentrations and pathologic changes present within 
TT joints.  To the authors’ knowledge, this is the first study to examine biomarkers in TT 
joints of older horses, and hope that it provides the template for future studies.  Our 
results suggest that C2C and IL-6 are the best biomarkers of those studied at 
distinguishing OA in TT joints.  In addition, more pathology was present in TT joints 
than expected based on radiographic examination, with no correlation to the PIT, DIT, 
and TMT disease processes. 
While radiography is a commonly performed diagnostic test for tarsal OA, TT 
joint OA is rarely associated with radiographic changes [46; 56].  It has even been 
pointed out that radiographs could not identify subchondral cysts in TT joints due to 
summation of opacities and overlapping contours [57; 58].  Our study supports these 
observations because 8 horses had normal TT joints on radiographs with the remaining 3 
only having mild changes.  Radiographs demonstrated low sensitivity because most TT 
joint pathology involved the synovial membrane and cartilage.  It is important to point 
out though that the 3 horses (horses 3, 8, and 9) with mild TT joint radiographic changes 
were grouped into the moderate disease subgroup based on total arthroscopic/gross score, 
suggesting that any TT joint abnormalities on radiographs, even if subtle, could be 
indicative of more severe pathology.  In addition, PIT joint radiographs did not correlate 
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to radiographic or arthroscopic/gross changes in TT joints, in contrast to previously 
suggested interconnections [45].  Therefore, radiographic changes in PIT joints could not 
be used to predict disease in TT joints.  This finding is most likely from the difference in 
function between these joints, despite direct communication. Nonetheless, radiographic 
changes in PIT joints also did not correlate to the similar functioning DIT or TMT joints, 
contradicting previous suggestions [46].   
The fact that radiographs do not adequately demonstrate presence or severity of 
TT joint OA is a problem because clinicians may miss clinically relevant disease.  This is 
especially important in older horses that have TT joint effusion, but also have a Churchill 
response and radiographic evidence of distal tarsal joint OA, as the assumption will be 
that the lameness originates from the distal joints.  This common clinical scenario was 
demonstrated in our case population. These findings did not help delineate whether the 
cause of lameness was from TT joints, distal joints, or both, emphasizing the need for 
thorough diagnostic analgesia in these cases.  Interestingly, the 2 horses donated for tarsal 
OA were part of the moderate TT joint OA subgroup and had grade 2 hindlimb lameness 
with at least moderate effusion, Churchill response, and flexion responses (Table 2.2) 
with variable radiographic OA of both TT and distal joints (Table 2.3).  This 
demonstrates that neither clinical nor radiographic signs of these horses could completely 
identify where lameness originated from in the tarsus.  Unfortunately, the way our study 
had to be set up, we were unable to perform diagnostic analgesia; thus we could not 
prove the origin of hindlimb lameness.  In addition, effusion grades, circumferential 
measurement, Churchill responses, lameness examination, and full limb flexion tests in 
case horses did not correlate to TT joint disease severity found on arthroscopic and gross 
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examination, making it difficult to draw conclusions from our clinical data.  Future 
studies that identify the exact source of lameness within the tarsus are needed to further 
delineate the usefulness of particular clinical signs in determining the relevance of TT 
joint OA with concurrent distal tarsal joint OA. 
Lack of information about TT joint OA from radiographs and clinical signs makes 
it important to investigate other diagnostics.  Arthroscopy is the gold standard diagnostic 
for determining cartilage and synovial changes within TT joints [45; 46; 108], but 
arthroscopic evaluation is not a practical screening tool in older horses.  Biomarkers of 
OA from SF of other joints have been successfully used to determine presence and 
severity of joint disease in horses [59; 73; 76-79; 83; 84; 88].  They have also been used 
to distinguish presence and severity of inflammation and cartilage damage related to TT 
joint OCD in young horses [72; 74; 100-104].  Therefore, using biomarkers to identify 
OA in TT joints is appealing, especially considering there is ample SF that can be 
collected.   
We could not identify significant differences between control and/or mild to 
moderate OA subgroups in any of the biomarkers studied, likely due to variability of the 
disease, combined with a low number of horses.  Since this was the first biomarker study 
of TT joint OA in older horses, we were unsure of the number of horses needed to obtain 
significance between groups.  Therefore, in an effort to promote future studies, we have 
supplied all of our biomarker data (Figures 2.4 and 2.5; Tables 2.6-2.8) because our study 
demonstrates potentially useful biomarkers for identifying OA in TT joints.  It is our 
hope that it will help researchers decide which biomarkers to examine and provide a basis 
for power calculations for future studies.   
	 	 	 34		
Our results highlight two biomarkers that may warrant future studies in larger 
populations: C2C and IL-6.  IL-6 was the only biomarker to correlate to multiple 
pathology scores in case horses, and when the controls and case horses were examined 
together, IL-6 and C2C were both positively correlated with cartilage arthroscopy/gross 
scores.  The control group was not examined arthroscopically, but their scores would be 
comparable to cartilage arthroscopy/gross scores performed on case horses since all 
arthroscopic lesions in case horses were confirmed grossly.  Even though there was no 
significant difference among groups (control, mild, and moderate) for C2C (P=0.080) and 
IL-6 (P=0.260), these correlations show that C2C and IL-6 concentrations increase with 
the severity of OA.  In fact, when looking at C2C data, ROC analysis demonstrated that 
187.44 pmol/ml could be used to distinguish disease, with horses being 3 times more 
likely to have disease when concentrations were >187.44 pmol/ml.  This is comparable to 
a young control horse population where the mean C2C concentration from TT joint SF 
was 170.9 ng/ml (equivalent to 176 pmol/ml) [74]. C2C concentrations for mild 
(mean±SD; 295.2±85.6 pmol/ml) and moderate (302.9±106.6 pmol/ml) subgroups in our 
study were more comparable to the presence of osteochondral fracture in carpi or fetlocks 
[72; 73] than those from TT joints with OCD in young horses [72; 74].  This makes sense 
since cartilage changes would likely be more widespread and deeper in older horses with 
OA than younger horses with OCD.  IL-6 is considered a modulatory cytokine because it 
can exhibit both pro- and anti-inflammatory properties.  Equine studies have shown that 
IL-6 is rarely present in SF in measurable concentration when joints are normal, but 
concentrations increase with worsening OA [84; 88], making it a good predictor of joint 
disease in horses [84].  Our results are comparable in that we had positive correlations 
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with pathology scores and had 6/11 of our TT joint concentrations below the lowest assay 
standard in control and mild groups compared with only 1 for the moderate group (Figure 
2.5; Table 2.7).  
Age has been demonstrated to affect biomarker concentrations [73; 100].  In most 
equine studies, biomarker levels were elevated in young populations in response to the 
developing/modelling musculoskeletal system.  This is clearly not the case in this study 
since all horses in our study were between 7-35 years.  Age positively correlated to 
cartilage arthroscopy/gross scores, IL-1β, and IL-10 for all horses and to arthroscopic 
synovial scores in case horses.  This suggests that as horses get older, there are more OA 
changes present in the synovial membrane and articular cartilage with variable cytokine 
responses.  There were no direct correlations between age and direct biomarkers 
suggesting, as others have [73], that this interaction is likely more complex. 
In our study, 4 case horses had communication of DIT and TMT joints with only 
1 horse having communication from distal joints to PIT and TT joints.  The number of 
horses with communication may be underestimated because we did not try to achieve 
maximal pressure as described by others using a similar medium [109].  Nonetheless, our 
results are similar to other study populations [109; 110].  We thought that horses with 
communication from distal joints might make TT joint OA worse, but based on our 
results, it is uncertain what role joint communication has on biomarker concentrations 
and OA status.  The one horse (horse 6) that had communication between all joints 
examined had much higher indirect biomarker concentrations compared to the other 
horses (Figure 2.5; Table 2.7), but relatively average direct biomarker concentrations 
(Figure 2.4; Table 2.6) with mild distal joint radiographic scores (Table 2.3). Based on 
	 	 	 36		
lack of radiographic disease, it is unknown if elevated indirect biomarker concentrations 
are from joint communication or individual horse variation. Additional studies comparing 
biomarker concentrations between joints with direct communication are needed to 
determine what effect communication has on biomarker concentrations across different 
stages of OA.  
It has been stated that arthroscopic surgery is the gold standard for OA diagnosis 
in TT joints [45; 46; 108].  Our results agree since the vast majority of lesions could be 
identified via arthroscopy, with gross examination only adding a median score of 3 per 
horse to the total pathology score.  However, it is important to note that while 
arthroscopy provided the most information on OA severity in TT joints, additional 
lesions may be present in locations that cannot be examined via arthroscopy such as the 
distal tibia.  It has been shown that lesions can be present on the distal tibia that can cause 
a substantial lameness [57; 58; 111].  These reports required the use CT and/or MRI to 
diagnose subchondral cystic lesions, which demonstrates the difficulty in identifying 
distal tibia lesions.  We identified distal tibia cartilage lesions in 7 horses in our study.  
Four of these horses had apparent cartilage degeneration at the periphery of the synovial 
fossa (Figure 2.3), with 3 of these 4 horses having additional focal cartilage lesions or 
score lines elsewhere on the distal tibia.  We could not identify any pattern of clinical, 
radiographic, arthroscopic, or biomarker changes that clearly helped identify distal tibia 
pathology.   
 Synovial fossae (normal cartilage-free depression) in TT joints have been reported 
to be present on the distal tibia, and in the intertrochlear groove, and medial trochlear 
ridge of the talus in horses [108; 112]. In our study, we found a wide array of 
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appearances of these synovial fossae; further study of these areas may be warranted, as it 
was difficult at times to determine if pathology was present surrounding them.  We 
considered them normal unless there appeared to be extension from what has been 
described.  On the distal tibia, we gave a score of 1 if there appeared to be a partial ring 
of thinning cartilage around the fossa periphery.  In addition, we also gave a score of 1 if 
the proximal and distal synovial fossa on the intertrochlear groove connected.  These 
areas may not be true lesions; since we did not perform histology we cannot say 
definitively one way or another.  Nonetheless, by giving low scores to those fossae that 
appeared different, we did not over-represent these findings.  On top of that, even if those 
scores were removed, the mild and moderate groupings of the horses would not change.  
There were several limitations in this study.  Only a small number of horses with 
wide ranging degrees of TT joint OA were enrolled.  Further studies are needed with 
larger numbers of horses, and our data can help researchers develop them.  In addition, it 
is difficult to obtain disease-free controls from an older population of horses.  Therefore, 
we had to use horses from a different study that did not have all the clinical, radiographic, 
arthroscopic, and biomarker end points as the current study.  This may mean that we 
classified some of these horses as controls, even though more pathology could have been 
identified if all modalities had been utilized.  Finally, we did not have the luxury of 
enrolling only those horses that had lameness localized to the tarsus.  This would be ideal 
for future studies since that would help determine if certain clinical signs represent the 
presence and/or severity of OA better than others. 
In conclusion, to the authors’ knowledge, this is the first study to examine 
biomarkers in TT joints of older horses, and hope that it provides the template for future 
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studies.  Our results suggest that C2C and IL-6 are the best biomarkers, of those 
examined, at distinguishing the presence of TT joint OA.  In addition, there was more 
pathology present in TT joints than could be seen on radiographs, with no correlation to 
PIT, DIT, and TMT disease; suggesting that arthroscopic surgery is still the best method 
to evaluate TT joint OA.  Based on our study, biomarkers could provide a valuable 
source of information about the OA disease process in TT joints that is currently only 
attainable with arthroscopic surgery, however further research is needed.  	
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CHAPTER 3: 
THE USE OF BIOMARKERS TO DETERMINE THE SEVERITY OF 
OSTEOARTHRITIS IN THE DISTAL INTERTARSAL AND 
TARSOMETATARSAL JOINTS OF OLDER HORSES 
 
 
Osteoarthritis (OA) commonly develops in the distal intertarsal (DIT) and 
tarsometatarsal (TMT) joints of performance horses (collectively termed “the distal tarsal 
joints”). Arguably, these joints are some of the most frequently medicated across 
disciplines since OA in the tarsal joints is one of the most common causes of pelvic limb 
lameness that limits performance in horses [44].  
Currently, the most common methods of identifying OA in the distal tarsal joints 
are physical, lameness, and radiographic examinations [47-49]. Physical examination 
includes conformation assessment and the response to the Churchill hock test which 
consists of application of pressure on first and second tarsal bones, and head of medial 
splint bone [47].  Lameness examination of horses with active distal tarsal OA often 
reveals a bilateral hind limb lameness and positive response to full limb flexion tests. 
Intra-articular anesthesia of the distal joints can also be used to localize the lameness.  
Radiography is the most common imaging modality used to assess OA in the distal tarsal 
joints, but many horses may have pain localized to these joints with minimal radiographic 
changes [48-54].  Radiographic evidence of OA (narrowed joint space, sclerotic bone, 
osteophytes, and bony bridging) takes time to develop, which is likely why radiographic 
findings are highly variable compared to clinical findings and the degree of lameness.  
For example, up to a 50% decrease in bone density can occur before changes are 
visualized on radiographs [55]. This points out that there is an important gap in our 
knowledge about the onset and progression of OA within these joints.  
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The main reason for this gap in knowledge is because accurate diagnosis of OA in 
the distal tarsal joints is difficult.  Readily attainable and reliable diagnostics are not 
available.  Compared to most other joints in the distal limb of the horse, additional 
diagnostics in the distal tarsal joints are limited. Arthroscopy is considered to be the 
“gold standard” for diagnosing cartilage lesions in most joints such as the tibiotarsal joint 
[108] (Chapter 2), but the small size of the distal tarsal joints prevents the use of this 
valuable diagnostic.  Since direct visualization of the distal tarsal joints is not possible, 
Magnetic Resonance Imaging (MRI) is considered the gold standard for evaluating them. 
MRI is a superior imaging modality in identifying specific anatomic lesions affecting 
cartilage, subchondral bone, synovium and surrounding soft tissues when compared to 
radiography, ultrasonography, and nuclear scintigraphy [61-64].  Unfortunately, MR 
imaging of the tarsus in a live horse in a high field magnet is often unattainable due to 
financial limitations as well as anatomical restraints of fitting the leg into some magnets 
with small bores.  The lack of a clear diagnostic tool to not only determine the presence 
of OA in the distal hock joints but to also track disease progression and response to 
treatment, often leads to over-treatment of these joints.  In fact, it is common clinical 
practice to inject the distal tarsal joints of horses with intra-articular corticosteroids up to 
every 6 months throughout horses’ careers even though there is plenty of suggestion in 
the literature that corticosteroid treatment into a joint is not benign [66-68].  Therefore, 
there is an urgent need for minimally invasive, reliable, quantitative diagnostic tests in 
horses that can detect early OA in these joints; ideally one that can then monitor the 
progression of OA such that the timing of treatment can be appropriately controlled.   
A novel way to detect early OA changes in the joint is through the measurement 
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of biomarkers from the synovial fluid (SF) from the joint of interest [35].  To the authors’ 
knowledge, there is only one biomarker study within the tarsus that has focused on OA in 
distal hock joints (specific to TMT joint) and found that certain biomarker assays may be 
useful in detecting early OA [105]. No study has examined biomarkers from the distal 
tarsal joints in a population of older horses and compared the biomarker changes to high 
field MRI.  
There were two objectives of this research.  The first objective was to compare 
the degree of OA found on radiographs to MRI in the distal tarsal joints.  The second 
objective was to measure SF concentrations of specific biomarkers from the distal tarsal 
joints to determine if they correlated to the following: (1) the degree of DIT and TMT 
OA identified on radiographs, (2) the degree of DIT and TMT OA identified on MRI and, 
(3) biomarker concentrations between the DIT and TMT joints. We hypothesized that (1) 
the degree of OA found on the radiographs would correlate to MRI but underestimate 
amount of OA present compared to MRI findings; (2) the biomarkers of the distal tarsal 
joints would correlate to the degree of OA identified on MRI more so than radiographs; 
(3) the biomarkers would be able to distinguish distal joints with moderate/severe OA 
from distal joints with mild OA, and (4) biomarkers would correlate to each other within 
each specific DIT and TMT joint.   
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Materials and methods 
 Horses were enrolled from a population of animals donated to the University 
(IACUC Approval #1411-32001A) for educational purposes (Chapter 2; Table 2.1). The 
inclusion criterion was radiographic evidence of tarsal OA in the distal tarsal joints that 
ranged from mild to severe using the following criteria: joint space narrowing, soft tissue 
swelling, subchondral bone sclerosis/lucency, and presence of osteophytes/enthesophytes.  
Both tarsi of each horse were radiographed using standard views (lateromedial, 
dorsoplantar, and dorsolateral to plantaromedial and dorsomedial to plantarolateral 
obliques).  The tarsus with the most overall radiographic changes was chosen as the limb 
of interest (Table 2.2), and radiographic scores were individually determined for each 
DIT and TMT joint (Table 3.1) using a modified scoring system [13] for a total possible 
score of 18 (Chapter 2; Table 2.3).  A blinded surgeon and radiologist scored the 
radiographs.  Mean scores were recorded.  
 Horses were then euthanized and DIT and TMT joint SF were obtained within 30 
minutes.  Samples from the DIT joint were collected on the medial aspect of the limb, 
just distal to the cunean tendon, at the junction of the central, third tarsal bone, and 
second tarsal bones.  The TMT joint SF samples were collected on the plantarolateral 
aspect of the limb, just proximal to the head of the fourth metatarsal bone.  SF samples 
were centrifuged, aliquoted, and stored at -80C° until further analyses.  
Contrast radiography was performed on the limb of interest to determine presence 
of direct communication between tarsal joints. Three mL of iohexol (Omnipaque 240e )  
were injected into the TMT joints, with needle placement verified by radiographs.  A 
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lateromedial radiograph was obtained to assess and record information.  This was 
repeated for the DIT joint. 
DIT and TMT joint SF was analyzed for several direct biomarkers using 
commercially available ELISAs. Carboxy-terminal propeptide of type II collagen (CPIIa) 
was measured to represent type II collagen synthesis.  Neoepitopes generated by 
collagenase cleavage of type II collagen (C2Ca) as well as C-terminal crosslinked 
telopeptides of type II collagen (CTXIIb) were measured for cartilage degradation. 
Aggrecan turnover was assessed using the chondroitin sulfate epitope 846 (CS846a) and 
early osteoblastic turnover was assessed using bone alkaline phosphatase (BAPc).  
Biomarkers were analyzed according to manufacturer instructions at appropriate 
dilutions.  
MR imaging was performed on the DIT and TMT joints.  All imaging was done 
on a GE Signa HD x 3.0 Tesla magnet.  Prior to imaging the limbs of interest, the 
feasibility of MRI of the tarsus was evaluated in a pilot study using two cadaver legs; one 
leg with and one leg without clinical and radiographic evidence of OA in the distal tarsal 
joints (Figure 3.1; images A-E).  For both the pilot and limbs of interest in the study 
population, the same protocol developed by a boarded radiologist, was used. T1-weighted 
images were acquired in the sagittal plane.  Proton density and T1-weighted images were 
used to evaluate morphological features associated with OA (joint effusion, synovial 
proliferation, subchondral bone sclerosis, number and size of osteophytes).  T2- weighted 
short tau inversion recovery (STIR) images were acquired in the sagittal plane to remove 
the signal from the subchondral bone fat and allow evaluation of subchondral bone 
hyperintensity.  Thin slices 3-Dimensional Fast Spoiled Gradient Recall (3D FSPGR) 
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were acquired in the sagittal plane, allowing high-resolution multiplanar reconstruction in 
any plane.  A multi-echo T2-relaxation mapping sequence was obtained in the sagittal 
plane.  The 3D-FSPGR and T2-relaxation mapping images were used to evaluate 
cartilage. Each joint from the limb of interest was graded according to several criteria, 
modified from previous grading scales [113].  Details of the grading scheme are available 
in Table 3.2, with the maximum possible MRI score being 21.   A boarded radiologist 
graded all MRIs.   
Gaussian distribution could not be assumed and no transformation was 
appropriate for all data.  Non-parametric Spearman’s rho tests were used to determine 
correlations amongst all horses for: age, DIT and TMT radiographic scores, total MRI 
scores, subcategory MRI scores, and biomarker concentrations.  Based on distal joint 
MRI scores, a clear line was evident to separate horses into subgroups of mild (score <7; 
DIT n= 5; TMT n=6) and moderate/severe (score ≥7; DIT n=6, TMT n=5) OA severity. 
Full data sets were not available for all biomarkers due to limitations in SF collection 
amount, and the number of horses in each group are indicated in the results section. The 
mild and moderate/severe OA groups were tested for normality using a Shapiro- Wilk 
normality test.  Data that passed the Shapiro-Wilk normality test were analyzed using a 
parametric Unpaired T test with Welch’s correction to compare ranks of biomarker 
concentrations between mild and moderate/severe OA groups.  This included the 
following: BAP, CPII, C2C, and CTX II in the DIT joint, and C2C and CS846 in the 
TMT joint.  Data that did not pass the Shapiro-Wilk normality test were analyzed using 
unpaired Mann-Whitney tests to compare ranks of biomarker concentrations between 
mild and moderate/severe OA severity groups.  This included the following: CS846 in the 
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DIT joint; BAP, CPII, and CTX II in the TMT joint.  MRI subgroups were compared 
between mild and moderate/severe OA groups in both the DIT and TMT joints using 
unpaired Mann-Whitney tests to compare ranks of grading categories. ROC analysis and 
Fisher’s exact test were performed to discriminate between mild and moderate/severe 
groups in the DIT and TMT joints using sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), likelihood ratio, and odds ratio. P values of 
≤0.05 were considered significant using statistical softwaref,g when applicable. 
 
Results 
Eleven horses met inclusion criteria for case horses, ranging in age from 9-35 
years old (mean=21 years). All eleven horses described in Chapter 2 had the DIT and 
TMT joints of the limb of interest analyzed.  The horse data is summarized in Tables 2.1 
and 2.2.  
Radiographic scores for the DIT and TMT joints are listed in Table 3.1.  In the 
DIT joint, radiographic scores ranged from 1-14.5 with a mean of 6.3, while the TMT 
joint radiographic scores ranged from 0.5 to 12.0 with a mean of 5.8.  The DIT and TMT 
radiographic scores were positively correlated (R=0.740, P= 0.009).   
 MRI scores for the DIT and TMT joints are listed in Table 3.2.  See Figures 3.2 
and 3.3 for examples of MR images obtained from study horses.  MRI scores for the 
distal joints were evaluated using the entire group (n=11) as well as by separating the OA 
severity in joints based on MRI scores into mild (<7) and moderate/severe (≥7).  In the 
DIT joint, 5 horses had mild OA and 6 horses had moderate/severe OA.  In the TMT 
joint, 6 horses had mild OA and 5 horses had moderate/severe OA.   
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 In the DIT joint, MRI scores ranged from 3-15 with a mean score of 7.6 points.  
The DIT joint radiographic and MRI scores were positively correlated (R=0.840, 
P=0.001). However, further analysis of DIT MRI (Table 3.3) demonstrated that MRI 
images provided more detail about the OA changes present than radiographs.  MRI 
demonstrated cartilage destruction in 9 horses (grades: 6 mild, 2 moderate, 1 severe).  
Mild joint effusion was present in 2 horses and moderate joint effusion was present in 1 
horse.  Synovial proliferation was not seen in any of the horses.  Subchondral bone 
sclerosis was noted in all DIT joints (grades: 3 mild, 7 moderate, 1 severe) and when 
compared to radiographs, MRI identified greater severity of subchondral bone sclerosis in 
4 horses.  However, there was no significant difference in the severity of subchondral 
bone sclerosis between the horses in the mild versus moderate/severe OA groups.  
Subchondral bone hyperintensity was identified in 6 horses (grades: 4 mild, 2 severe).  
Results of DIT joint MRI categories mild OA (<7) and moderate/severe OA (≥7) groups 
are available in Table 3.3.  Significant differences between groups were present in 
subchondral bone hyperintensity (P=0.022).  Within MRI subcategories, subchondral 
bone hyperintensity was correlated to the number of osteophytes (R= 0.748, P= 0.012) 
and to the amount of cartilage destruction (R=0.630, P= 0.030); subchondral bone 
sclerosis was correlated to the number of osteophytes present (R=0.600, P= 0.050).   
 In the TMT joint, MRI scores ranged from 3-14 points with a mean of 7.2.  The 
TMT joint radiographic and MRI scores were positively correlated (R=0.870, P= 0.001).  
However, further analysis of TMT MRI (Table 3.4) demonstrated that MRI provided 
more detail about the OA changes present than radiographs.  MRI demonstrated 10 
horses with cartilage destruction (grades: 6 mild, 3 moderate, 1 severe).  Mild joint 
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effusion was identified in 2 horses, with no synovial proliferation seen in any of the 
horses.  Subchondral bone sclerosis was noted in all horses (grades: 4 mild, 6 moderate, 1 
severe) and when compared to radiographs, MRI identified greater subchondral bone 
sclerosis severity in 4 horses, and decreased severity in 1 horse.  Subchondral bone 
hyperintensity was identified in 4 horses (grades: 2 mild, 1 moderate, 1 severe).  
Osteophytes were identified in all TMT joints on MRI and when compared to 
radiographs, additional osteophytes in number and size were only identified in 1 horse 
(horse 5).  Results of TMT joint MRI subcategories mild OA (<7) and moderate/severe 
OA (≥7) groups are available in Table 3.4.  Significant differences between groups were 
present in cartilage destruction severity (P= 0.013), SCB hyperintensity severity (P= 
0.015), and the size of the largest osteophyte (P= 0.015).  Within MRI categories, 
subchondral bone hyperintensity was correlated to the number of osteophytes (R= 0.876, 
P= 0.004) and the size of the largest osteophyte present (R= 0.712, P= 0.014).  TMT joint 
cartilage destruction severity was also correlated to the size of the largest osteophyte (R= 
0.754, P= 0.014).  
 When comparing the DIT and TMT joint MRI results, the DIT joint had mildly 
increased severity of OA but overall disease present was similar with mean total MRI 
scores of 7.6 and 7.2, and the scores correlated to each other (R=0.662, P= 0.030).  
Subchondral bone sclerosis was found in all DIT and TMT joints and their severity was 
correlated (R=0.699, P= 0.021).  Nine horses had cartilage destruction in both joints 
concurrently but severity was not correlated. The number and size of osteophytes were 
similar between the joints but were not correlated.  
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The amount of SF collected from the DIT joints ranged from 0-2.0 mL with an 
average collection volume of 0.45 mL.  The amount of SF collected from the TMT joints 
ranged from 0-1.0 mL with an average collection volume of 0.4 mL.  Biomarker dilutions 
used and concentrations obtained for the distal joints are available in Tables 3.5 and 3.6.  
Correlations between biomarker concentrations are available in Table 3.7.  The 
separation of DIT and TMT OA groups based on MRI scores into mild (<7) and 
moderate/severe (≥7) are represented graphically in Figures 3.4 and 3.5. In the DIT joint, 
5 horses had mild OA and 6 horses had moderate/severe OA.  In the TMT joint, 6 horses 
had mild OA and 5 horses had moderate/severe OA.  
BAP concentrations from the DIT joint were available for 9 horses. As an entire 
group, DIT joint BAP concentrations were strongly correlated to total MRI scores (R= 
0.932, P=0.001). The DIT joint BAP concentrations were also correlated to cartilage 
destruction (R= 0.772, P= 0.016), subchondral bone hyperintensity (R= 0.767, P= 0.025), 
number of osteophytes (R=0.757, P= 0.032), and the size of the largest osteophyte (R= 
0.730, P= 0.048).   When examining BAP concentrations after horses were split into DIT 
joint MRI scores of mild (n=4) and moderate/severe (n=5), moderate/severe horses had 
significantly higher BAP concentrations (mean of 33.2 U/L) than mild (mean of 13.57 
U/L) horses (P= 0.039; Figure 3.4). Based on ROC analysis, a BAP concentration of 25 
U/L was used to determine predictive value (0.048) for discriminating moderate/severe 
OA in the DIT joint (MRI score ≥ 7) yielding: sensitivity=80%, specificity=100%, 
PPV=100%, NPV=80%, a positive likelihood ratio of 8, and an odds ratio of 27. BAP 
concentrations in the TMT joint were higher in the moderate/severe OA group (mean of 
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24.84U/L) compared to the mild OA group (mean of 17.66 U/L) but were not statistically 
different (P= 0.904; Figure 3.5).  
CPII concentrations from the DIT joint were available for 8 horses.  As an entire 
group, DIT joint CPII concentrations were strongly correlated to DIT joint subchondral 
bone hyperintensity (R=0.809, P= 0.029) and to total DIT joint MRI scores (R=0.743, 
P=0.042).  When examining CPII concentrations after horses were split into DIT joint 
MRI scores of mild (n=4) and moderate/severe (n=4), moderate/severe horses had 
significantly higher CPII concentrations (mean of 2387 ng/mL) than mild (mean of 1094 
ng/mL) horses (P= 0.034; Figure 3.4).  Based on ROC analysis, a CPII concentration of 
1405 ng/mL was used to determine a predictive value (P= 0.028) for discriminating 
moderate/severe OA in the DIT joint (MRI score ≥7) yielding sensitivity=100%, 
specificity=100%, PPV = 100%, NVP= 100%.  CPII concentrations from the TMT joint 
were available for 8 horses.  As an entire group, the CPII concentrations correlated to 
total TMT joint MRI scores (R=0.634, P= 0.047).  When examining CPII concentrations 
after horses were splint into TMT joint MRI scores of mild (n=6) and moderate/severe 
(n=2), moderate/severe horses had higher CPII concentrations (mean of 2880.5 ng/mL) 
than mild horses (mean of 1697.7 ng/mL), but were not significantly different (P=0.071; 
Figure 3.5).  
C2C concentrations from the DIT joint were available for 10 horses.  As an entire 
group, C2C concentrations correlated to DIT joint subchondral bone hyperintensity 
identified on MRI (R= 0.804, P= 0.010) and total DIT joint MRI score (R=0.640, 
P=0.046).  When examining C2C concentrations after horses were split into DIT joint 
MRI scores of mild (n=5) and moderate/severe (n=5), moderate/severe horses (mean of 
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292.4 pmol/mL) had significantly higher C2C concentrations than mild (mean of 200.9 
pmol/mL) horses (P= 0.008; Figure 3.4).  Based on ROC analysis, a C2C concentration 
of 240 pmol/mL was used to determine a predictive value (P=0.038) for discriminating 
moderate/severe OA in the DIT joint (MRI score ≥ 7) yielding: 100% sensitivity, 100% 
specificity, PPV = 100%, NPV= 100%.  In the TMT joint, C2C concentrations were 
higher in the mild OA group (mean of 224.3 pmol/mL) than the moderate/severe OA 
group (mean of 214.8 pmol/mL) but were not statistically different (P=0.762).  
CTX II concentrations from the DIT joint were available for 9 horses.  As an 
entire group, DIT joint CTX II concentrations were correlated to subchondral bone 
sclerosis severity identified on MRI (R= 0.689, P= 0.044). When examining CTX II 
concentrations after horses were split into mild (n=4) and moderate/severe (n=5) groups, 
moderate/severe horses had higher CTX II concentrations (mean of 25.29 pg/mL) than 
mild horses (mean of 17.11 pg/mL) but were not significantly different (P= 0.286; Figure 
3.4).  However, it should be noted that one horse in the mild group (horse 7) had a much 
higher value (48.57 pg/mL) than the rest of the mild horses (mean value of 6.63 pg/mL), 
potentially skewing the data.  In the TMT joint, results were available for 7 horses.  
When examining CTX II concentrations after horses were divided into mild OA (n= 5), 
and moderate/severe OA (n=2) groups, the mild OA group had higher CTX II values 
(mean of 15.58 pg/mL) than the moderate/severe OA group (mean of 13.7 pg/mL), but 
were not statistically different (P=0.857; Figure 3.5).  
CS846 concentrations from the DIT joint were available for 9 horses. When 
examining CS846 concentrations after horses were splint into DIT joint MRI scores of 
mild (n=4) and moderate/severe (n=5), mild OA horses had higher CS846 concentrations 
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(mean of 7104 ng/mL) than moderate/severe OA horses (mean value of 5720 ng/mL), but 
were not significantly different (P=0.114; Figure 3.4).  In the TMT joint, CS846 
concentrations were available for 9 horses.  As an entire group, CS846 concentrations 
correlated to the amount of cartilage damage identified on MRI in the TMT joint (R= 
0.697, P=0.032). When examining CS846 concentrations after horses were splint into 
TMT joint MRI scores of mild (n=6) and moderate/severe (n=3), mild OA horses had 
higher CS846 concentrations (mean of 6953 ng/mL) than moderate/severe OA horses 
(mean of 4356 ng/mL), but were not significantly different (P=0.547; Figure 3.5).   
Contrast radiography identified direct communication between TMT and DIT 
joints in 4 horses (36%), with one (9%) of these also communicating with PIT and TT 
joints (Table 2.3).  Two horses had mild DIT and TMT OA, and 2 horses had moderate 
DIT and TMT OA based on MRI scores. The presence of distal joint communication was 
not correlated with imaging or biomarker results. When looking at concentrations 
between the joints that communicated there were no similarities in concentrations 
between the joints for any of the biomarkers examined with the exception of C2C in 2 
horses that had mild OA in both the DIT and TMT joints (horse 5 and 6).  
Discussion 
To the authors’ knowledge, this is the first study that examined the correlation of 
OA disease severity in the distal tarsal joints of older horses with radiographs, MRI, and 
biomarkers of OA.  We hope this provides a template for future studies of biomarkers in 
the equine tarsus.  This study demonstrated that MRI provides superior detail compared 
to radiographs and could be useful in identifying early tarsal OA.  Of the biomarkers 
examined BAP, CPII, and C2C correlated to DIT joint OA severity and could distinguish 
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moderate/severe from mild disease.  In the TMT, none of the biomarkers analyzed could 
be used to determine moderate/severe OA from mild OA.  
Radiographs of the DIT and TMT joints correlated to the MRI scores.  The DIT 
joint had slightly more pathology than the TMT joint on both radiographs and MRI, 
similar to previous studies [51; 54; 114].   The variance in disease severity may be due to 
the difference in the bones that make up the DIT and TMT joints.  The DIT joint is 
encompassed by small tarsal bones on both the proximal and distal articular surfaces. As 
the joint is loaded, forces are spread across the proximal and distal row of tarsal bones 
that have a small area to disperse such forces.  The TMT joint has a proximal surface of 
small tarsal bones, but the distal surface is composed of the larger metatarsal bones, with 
the third metatarsal bone bearing most of the weight.  The larger bone has more area to 
disperse forces placed upon it, protecting the TMT joint.  Comparing radiographs to MRI, 
radiographs were a good indicator of OA for the distal tarsal joints in this population.  10 
of 11 horses were put in the same mild or moderate/severe groupings for the DIT joint 
and 9 of 11 horses for the TMT joint based on the grading scales used. However, 
radiographs did underestimate the degree SCB hypointensity (sclerosis), number of 
osteophytes, and size of osteophytes in many of the cases.    
The advantage to using MRI for the distal tarsal joints is to identify boney and 
cartilaginous abnormalities with greater sensitivity compared to radiographs, and to find 
OA changes unidentifiable on radiographs to allow early detection of OA.  An area where 
MRI was more sensitive than radiographs was SCB sclerosis severity.  Knowing the 
presence of SCB sclerosis could help clinically localize lameness to the tarsus.  A 
previous study showed that when subchondral bone sclerosis is present in the tarsus, 
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intra-articular anesthesia does not always block out pain, altering the interpretation of the 
block [63].  In this study, SCB sclerosis was found in all DIT and TMT joints on MRI.  
On radiographs, SCB sclerosis was identified in most of the joints (10 of 11 DIT and 
TMT joints), however, the severity of SCB sclerosis found on MRI compared to 
radiographs was greater in 4 DIT joints and 3 TMT joints.  There is evidence to support 
that SCB sclerosis precedes articular damage in OA [32; 40-42].  The mechanism of 
action for the initial subchondral bone changes likely originates with the joint receiving 
abnormal forces from either traumatic injury or chronic irregular weight bearing (such as 
poor conformation).  The subchondral bone is damaged and thickens in the process of 
remodeling.  The incongruities of areas of thick and normal subchondral bone create 
abnormal shear forces on the overlying cartilage that lead to cartilage damage and 
fibrillation [32].  In fact, in this population, SCB sclerosis severity had a higher grade 
than cartilage destruction in 9 of 11 DIT and TMT joints suggesting these joints have 
more SCB damage than articular damage. Therefore, early identification is valuable and 
could allow treatment or exercise changes before cartilage damage occurs.  
 Of the MRI subcategories evaluated, SCB hyperintensity separated the 
moderate/severe from mild OA in the DIT and TMT joints the best. Similar to previous 
studies, SCB hyperintensity had the greatest visualization on the T2-weighted STIR 
images [63; 115]. SCB hyperintensity can occur from any combination of bone marrow 
necrosis or fibrosis, and bone edema [63].  In humans, it has been noted that SCB 
hyperintensity viewed on T2 STIR images could be indicative of reactive sclerosis with 
newly formed fibrovascular tissue, versus mature sclerosis that often appears hypointense 
[65].  If horses act in a similar manner, identification of SCB hyperintensity could be a 
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good indicator of early and active disease since it has been stated that SCB hyperintensity 
of the distal tarsal joints may correlate with clinical lameness [63].  In the study 
population, SCB hyperintensity was found in 100% of the moderate/severe OA DIT 
joints and was not present in any of the mild DIT joints.  In the TMT joint, SCB 
hyperintensity was found in 4 of 5 (80%) of the moderate/severe OA joints and was not 
present in any of the mild joints.  These findings suggest that the presence of SCB 
hyperintensity is indicative of moderate/severe OA. Identifying SCB hyperintensity is a 
great advantage of MRI since it is not visualized on radiographs. Although our results 
clearly demonstrate the value of MRI when evaluating the distal tarsal joints, it is 
important to remember that the availability of the MRI is limited due to financial 
constraints.  In addition, to get comparable images to those examined in this study, there 
is a need for anesthesia and the ability to get the distal tarsal joint far enough into 
magnets with smaller bores.  It is unknown as to whether these changes could be 
identified using standing MRI units, but it is worth further investigation.  The 
discrepancy in information gathered on MRI versus radiographs is an area where 
biomarkers have a potential valuable role, specifically in terms of SCB hyperintensity 
and cartilage damage.  
Unlike previous studies, age did not correlate to any biomarker concentrations, 
[73; 116]. This discrepancy is most likely because this population consisted of all mature 
horses while many previous studies looked at younger horses still in the process of 
maturing musculoskeletally, either through skeletal growth or exercise-related 
development.  One problem with examining an older population of horses, however, was 
that finding normal control horses is difficult since many horses in this age range have 
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distal tarsal joint OA.  In addition, it is difficult to identify subtle OA changes in the 
distal tarsal joints since gross examination is unreliable due to the difficulty in 
disarticulating these joints.  This is why mild and moderate/severe OA groups were 
identified in this study based on total MRI scores, even though the degree of OA could 
have been underestimated on MRI and radiographs, especially with regards to articular 
cartilage. While it would be ideal to have normal controls for comparison, it was felt that 
by dividing the horses into two groups based on MRI severity, it would be possible to see 
if the biomarkers could distinguish those with greater disease severity from milder 
changes.   
 In general, the biomarkers examined were able to distinguish the severity of OA 
in the DIT joint more than the TMT joint.  There was less separation in the TMT joint 
than in the DIT joint when mild and moderate/severe OA groups were formed, lowering 
the statistical power and ability to distinguish a difference between groups.  Additionally, 
less data was available for biomarkers of the TMT joint moderate/severe OA group for 
most of those examined compared to the DIT joint..  
Of the biomarkers examined, those that represent synthesis of the matrices 
appeared to be the best indicators of OA in this population.  In the DIT joint, BAP and 
CPII were the best at distinguishing OA severity, and had the highest correlation to total 
MRI DIT scores.  In the TMT joint, CPII had the highest correlation to total TMT joint 
MRI scores. The up-regulation of synthetic biomarkers is indicative of early OA, while 
end stage OA results in an increase in degradation with a decreased production of bone 
and cartilage [35]. Therefore, despite MRI scores ranging from mild to severe, the global 
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degree of OA in these joints was not yet end stage, as they were still able to regenerate 
bone and cartilage.   
BAP, a marker of early osteoblastic activity is increased in environments of bone 
turnover [82]. A value of 25 U/L was able to distinguish all but one horse with 
moderate/severe disease compared to those with mild OA.  More importantly, BAP also 
correlated to several MRI subcategories such as SCB hyperintensity, a finding that cannot 
be identified via radiographs. Of the 6 horses with SCB hyperintensity, BAP values were 
available for 5 horses.  Of the 5 horses, 4 of them had BAP values over 25 U/L.  
Therefore, BAP concentrations have the potential to provide important information about 
the severity of disease in the DIT joints of horses in which MRI is not an option.  It is 
interesting to note that BAP concentrations reported in this study in the mild and 
moderate/severe DIT joint groups were similar to concentrations reported in previous 
studies of normal and diseased carpal and fetlock joints, respectively [59; 83].  Within the 
TMT joint, similar trends occurred but were not significant.  While BAP from the TMT 
joint SF could also potentially be useful, only three samples were available for 
moderate/severe OA horses.  
CPII measures an epitope of protein fragments produced when type II collagen is 
synthesized [70].  In early OA, cartilage production increases secondarily to cartilage 
degradation [117], which could be why CPII concentrations are increased.  It has been 
shown in humans that as cartilage damage continues during OA, eventually synthesis 
cannot keep up with degradation and CPII concentrations are lower in end stage OA [71].  
In this population, CPII was the only biomarker that correlated to OA severity in both of 
the distal tarsal joints; CPII concentrations from the DIT and TMT were correlated to 
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both total MRI and radiographic scores.   This demonstrated that even as the disease 
severity increases, the CPII concentration continued to increase, showing the ability for 
these joints to still synthesize cartilage, indicating some capacity to heal. A CPII 
concentration of 1405 ng/mL in the DIT joint separated moderate/severe from mild OA 
joints in all horses. The DIT joint CPII concentrations in horses with mild OA were 
similar to values from previous studies in normal adult and young horse fetlock joints; 
moderate/severe OA DIT joint concentrations were similar to young horses with OC 
affected fetlock joints [73].  Both the DIT and TMT joint concentrations were higher than 
those found in young horses with normal and OCD affected TT joints [74], and lower 
than young horses with carpal bone fractures [72].  In humans, CPII was able to predict 
successive radiographic changes in early knee OA [17].  In this study, we found CPII was 
correlated to both radiographic and MRI scores of the distal joints, so in future studies it 
would be interesting to follow horses out for longer periods of time starting earlier in the 
OA disease process to see if there are similar trends.  
C2C was the best biomarker of degradation examined as it correlated to total DIT 
joint MRI scores and DIT joint subchondral bone hyperintensity.  C2C measures the 
degradation of type II collagen by identifying the neoepitope created after collagenase 
cleavage of the collagen triple helix at the ¾ fragment of the carboxy terminus region 
[16].  The cleavage of type II collagen is an abnormal finding in a joint and increases 
when the cartilage matrix is disturbed, as occurs in OA [80].  In this study population, a 
DIT joint C2C concentration of 240 pmol/mL was able to distinguish moderate/severe 
horse from all mild OA horses.   C2C concentrations in the DIT joint were also strongly 
correlated to SCB hyperintensity, making it a potentially useful biomarker clinically.  
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Within the DIT joint, C2C concentrations correlated to CPII concentrations (Table 3.7), 
demonstrating the simultaneous cartilage degeneration and regeneration occurring in the 
joint.  C2C concentrations of the mild OA DIT joints were similar to C2C values found in 
synovial fluid from normal adult horse (median age 4 years) metacarpophalangeal joints 
[73].  C2C concentrations of the moderate/severe OA DIT joints were similar to 
metacarpophalangeal joints with osteochondral injury [73], and to young horses (median 
age 2) with carpal bone fractures [72].  Interestingly, C2C did not distinguish OA severity 
in the TMT joint, despite similar amounts of cartilage damage determined on MRI.  
However, as mentioned previously, the amount of cartilage damage may have been 
underestimated on MRI.   It is possible that there could have been more pathology in the 
DIT joint compared to the TMT joint than determined in the study. Further research is 
warranted.   
The two biomarkers that did not correlate to total MRI scores or separate 
moderate/severe from mild OA in the distal tarsal joints were CTX II and CS846. CTX II 
is a catabolic biomarker that is a measurement of type II collagen degradation [69].  It 
should be noted that with the exception of one value (horse 7, CTX II = 48.57 pg/mL), 
mild OA horses had lower CTX II concentrations (< 10 pg/mL) than the moderate/severe 
groups (>20 pg/mL).  While significant differences were not noted between groups, CTX 
II is a biomarker that would be worth studying further. The CTXII concentrations in the 
DIT and TMT joints in both mild and moderate/severe OA categories were lower 
compared to a previous studies evaluating CTX II in the middle carpal and 
metacarpophalangeal joints in young horses with osteochondral injury [78], but were 
similar to values in another study in horses that developed traumatic OA of the 
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metacarpophalangeal joint from time of injury to two years after [79].  The lack of 
success of CTX II to distinguish OA severity in this study could be from the low number 
of horses enrolled or because the joints are still predominately in the anabolic stage of 
OA.  Future studies with long-term follow up would be beneficial to evaluate if CTX II 
increases as OA progresses.  CS846 is a biomarker that measures fetal forms of aggrecan 
that is normal in young animals, but only seen in adult animals when repairing cartilage 
[80].  CS846 concentrations in this study did not correlate to MRI scores and were not 
different among mild and moderate/severe DIT or TMT joints in this study, again, 
possibly due to underestimating OA severity on MRI.  The concentrations of the groups 
were similar to those of polo ponies that developed arthritis in the metacarpophalangeal 
joints within 24 months compared to horses that did not develop OA [81] and to 2 year 
old horses with induced OA in the middle carpal joints after about 50 days of treadmill 
exercise  [76].  The concentrations in the mentioned studies showed elevations of CS846 
overtime.  The older population in this study may have already had initial CS846 
concentration increases and are now in a chronic steady state.  Further research is 
warranted to follow older horses out for a longer period of time to see if CS846 
concentrations would elevate further, or decline as the disease progresses.  
In joints with direct anatomic communication, biomarker concentrations between 
the joints were not similar.  We demonstrated similar communication patterns as those 
reported in previous studies between the DIT and TMT (36%), as well as up to the PIT 
and TT Joints (9%) [109; 110].  In the study population, it appears that each joint has its 
own microenvironment and the biomarker concentrations reflected pathology specific to 
each individual DIT or TMT joints.  The number of horses with communication in this 
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study was low, so further research is needed to determine the impact of anatomical joint 
communication on biomarker concentrations.  
A potential clinical challenge of using biomarkers in the distal tarsal joints could 
come in the ability to collect enough synovial fluid. The following amounts of SF are 
needed to run the following biomarkers of interest, in duplicates: 0.05 mL for C2C, 0.032 
mL for CPII, and 0.04 mL for BAP; totaling 0.122 mL.  A mean SF sample of 0.4 mL 
was collected in the DIT and TMT joints in this study, but SF sample collection was 
performed after euthanasia, allowing larger needles to be used for collection than may be 
possible in the live horse.  With that said, it is still possible to get fluid back when 
performing synoviocentesis or joint injections on the distal tarsal joints in some clinical 
cases.  However, a recent study showed that accuracy of getting a needle into the TMT 
joint is high (96%), while much lower in the DIT joint (42%) [118], so radiographic 
guidance may help with accurate needle placement for SF collection.  In this study, the 
amount of SF collected from the distal joints limited the number of biomarkers that could 
be evaluated. Future studies could look at additional direct and indirect biomarkers.  
Another limitation of this study was that only a small number of horses were enrolled.  
Further research is warranted with a larger number of horses. In addition, it is difficult to 
obtain disease-free controls, as many older horses have a degree of OA in the distal tarsal 
joints, so further studies may have to divide the population into mild and moderate/severe 
OA as done here.  Finally, the focus of this study was on the amount of OA present on 
MRI compared to biomarker concentrations, not clinical lameness.  Future research with 
horses with lameness localized to the tarsus would be advantageous.   
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Conclusions: Radiographs of the DIT and TMT joints correlated to the 
corresponding MRIs in this study but underestimated the degree of SCB bone sclerosis, 
and number and size of osteophytes in many of the cases.  MRI was more sensitive in 
identifying these abnormalities and provided information about cartilage damage and 
SCB hyperintensity.  The severity of SCB sclerosis and presence of SCB hyperintensity 
was a good indicator for separating moderate/severe from mild OA.  Of the biomarkers 
evaluated, synthetic biomarkers were the best in identifying OA and separating 
moderate/severe from mild disease.  The biomarkers of synthesis with the highest 
correlation to disease in the DIT joint were BAP and CPII and in the TMT was CPII. Of 
the catabolic biomarkers, C2C correlated to total MRI score and to CPII in the DIT joint.  
In the DIT joint, BAP, CPII, and C2C also correlated to SCB hyperintensity.  This 
demonstrates the potential use of biomarkers to give information relevant to detecting 
early OA that is not visible on radiographs.  Early identification of OA could help guide 
treatment and training regimens to better shape the career and longevity of the equine 
athlete.  
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Chapter 4:  
The use of biomarkers from the tibiotarsal joint to determine osteoarthritis in the 
distal intertarsal and tarsometatarsal joints in horses 
 
The tarsus is comprised of 5 joints: the tibiotarsal (TT), proximal intertarsal (PIT), 
distal intertarsal (DIT), tarsometatarsal (TMT), and talocalcaneal (TC) joints.  The DIT 
and TMT joints (collectively termed “distal tarsal joints”) are prone to developing 
osteoarthritis (OA).  Biomarkers of OA can be collected from the synovial fluid from the 
joint of interest and measured (Chapters 2 and 3).  The main challenge in using 
biomarkers to measure OA in the distal tarsal joints is the ability to collect synovial fluid 
due to their small size.  However, the tibiotarsal (TT) joint is much larger and repeated 
synoviocentesis is easily achievable.  The TT joint and proximal intertarsal (PIT) joint 
always communicate anatomically.  The distal tarsal joints communicate up to 36% and 
direct communication between the TT joint and distal hock joints is uncommon, ranging 
from 1-4% [109; 110].  However, functional communication may be increased between 
the proximal and distal tarsal joints.  It has been shown in a previous study that when 
smaller molecules like steroids are examined versus using traditional latex or Iohexol to 
determine joint communication, functional communication in the distal tarsal joints was 
found to be up to 100% [119]. Therefore, it may be possible for small biomarkers of OA 
to diffuse between joints in a similar manner.  Clinically, it has been noted that after 
distal joints are treated with corticosteroids in some horses, effusion in the tibiotarsal 
joint decreases.  If synovial fluid from the tibiotarsal joint can provide information about 
disease in the distal tarsal joints, it could serve as a quantitative method of evaluating OA 
in the DIT and TMT joints and provide a means for veterinarians to have an objective 
method to diagnose, stage, and determine response to treatment of OA.  The first 
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objective of this research was to see if SF from the TT joint could be used to assess OA 
in the distal joints by comparing specific SF biomarker concentrations in the TT/PIT 
joints from older horses with varying degrees of OA and determine if they correlate to the 
following: (1) the degree of PIT, DIT, or TMT joint OA identified on radiographs, (2) the 
degree of PIT, DIT, or TMT OA identified on MRI, (3) specific SF biomarker 
concentrations from the DIT and TMT joints. 
 
Materials and methods 
Refer to Chapters 2 and 3 for detailed materials and methods.  The PIT joints 
from the legs of interest were also imaged with MRI and graded under the same protocol 
as the DIT and TMT joints.  Biomarkers examined in the TT/PIT joints are listed in 
Tables 2.6 and 2.7 and the biomarkers examined in the distal joints are listed in Tables 
3.5 and 3.6.  
 Gaussian distribution could not be assumed and no transformation was 
appropriate for all data.  Non-parametric Spearman’s rho tests were used to determine 
correlations between the proximal (TT and PIT) joints and the distal (DIT and TMT) 
joints for: radiographic scores (TT, PIT, DIT, TMT joints), MRI scores (PIT, DIT, TMT 
joints), and biomarker concentrations (TT/PIT, DIT, TMT joints).  Non-parametric Mann 
Whitney tests were used to compare mild (MRI score <7) and moderate/severe (MRI 
score ≥7) DIT and TMT joints (Chapter 3) using TT SF values. 
 
 
 
	 	 	 64		
Results  
 Radiographic scores for the TT, PIT, DIT, and TMT joints are listed in Table 2.3.  
Radiographic scores from the proximal joints did not correlate to radiographic scores of 
the distal joints.  Radiographic scores in the proximal joints were lower compared to the 
distal joints and were highest in the DIT joint.  The mean radiograph scores for the joints 
of interest were: 0.5 in the TT joint, 2.6 in the PIT joint, 6.3 in the DIT joint, and 5.8 in 
the TMT joint.   
MRI scores were available for the PIT, DIT, and TMT joints.  Specific MRI 
findings for the distal joints are available in the Chapter 3 results section.  PIT joint 
radiographic and MRI scores are available in Table 4.1.  No correlations existed between 
the distal joints and the PIT joint MRI scores.  Similar to the distal joints, additional 
pathology was identified in the PIT joint on MRI compared to radiographs.  In the PIT 
joint, MRI scores ranged from 1-8 with a mean of 4.2 out of a possible 21 points.  Joint 
effusion was noted in 5 horses (4 mild, 1 moderate).  Mild cartilage destruction was 
identified in 3 horses. Synovial proliferation was identified in 3 horses (2 mild, 1 severe).  
Subchondral bone sclerosis was noted in all PIT joints and when compared to 
radiographic findings, the severity was greater in 5 horses.  Subchondral bone 
hyperintensity was not identified in any PIT joints.  The number of osteophytes found on 
MRI compared to radiographs was decreased, with more found on radiographs in 3 
horses.  The size of the largest osteophyte in the same 3 horses in which additional 
osteophytes were found was also graded larger on radiographs compared to MRI.   
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 Comparing PIT joint MRI results to the distal joints, globally less disease was 
present.  Overall mean MRI scores were lowest in the PIT joint.  Cartilage damage was 
less severe compared to the distal joints in 7 horses.  In contrast to the distal joints, no 
subchondral bone hyperintensity was found around any PIT joints. Subchondral bone 
sclerosis in the PIT joint was similar to the distal joints.  A decreased number of 
osteophytes were found in 8 of the PIT joints. 
 OA in the TT joint was assessed by arthroscopy and gross examination (Table 
2.4).  TT joint arthroscopy scores negatively correlated to DIT radiographic scores (R= -
0.620; P=0.042) and did not correlate to PIT or TMT joint radiographic scores.  
Arthroscopy scores did not correlate to PIT, DIT, or TMT joint MRI scores.   
Correlations between proximal and distal tarsal joint biomarker concentrations are 
available in Table 4.2.  In summary, all correlations identified were negative.   When TT 
joint biomarkers were assessed based on the severity groupings of the distal joints that 
were determined by MRI (i.e. mild or moderate/severe), TT concentrations for all 
biomarkers were unable to distinguish any difference between the groups (Figures 4.1-
4.4).  
Discussion 
Biomarkers have a potential role in identifying early OA in the distal tarsal joints 
of horses (Chapter 3) but a clinical limitation is the amount of synovial fluid that can be 
collected from the small DIT and TMT joints.  In contrast, synoviocentesis is easy in the 
TT joint.  It would be ideal if there were a biomarker that could be measured from TT SF 
that correlated to distal tarsal joint OA.  However, the results of this study did not identify 
such a biomarker.  Of the biomarkers examined from the TT SF, none of them correlated 
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to disease in the distal joints.  Biomarkers of the TT SF only had negative correlations to 
biomarkers from the distal tarsal joints (Table 4.2). 
When evaluating the TT joint biomarker concentrations based on the DIT and 
TMT OA severity (mild <7 MRI score, moderate/severe ≥	7	MRI	score) groups,	there	were	no	differences	observed	between	groups	(Figures	4.1-4.4).		In	addition,	TT	joint	biomarker	concentrations	did	not	correlate	to	distal	tarsal	OA	severity	on	MRI,	and	imaging 
of the TT joint (radiographs, arthroscopy, gross pathology) did not correlate to distal joint 
imaging (radiographs, MRI).  
In the study population, 4 horses had communication between joints, 3 between 
the DIT and TMT joints, and 1 with communication from the distal joints all the way to 
the TT joint.  Similar to findings in Chapter 2 and 3, joints with anatomic communication 
determined by contrast radiology did not have similar biomarker concentrations among 
them.  Further research is warranted to determine the role of joint communication and 
OA. 
Limitations: Only a small number of horses were enrolled in the study.   In 
addition, it is difficult to obtain disease-free controls, as many older horses have a degree 
of OA in the distal tarsal joints, so further studies may have to divide the population into 
mild and moderate/severe OA as done here.  Finally, the focus of this study was on 
amount OA present on MRI compared to biomarker values, not clinical lameness.  Future 
research with horses with lameness localized to the tarsus would be advantageous.   A 
larger sample size with a broader range of OA would be ideal to evaluate biomarker 
value trends.   
In conclusion, the results of this study suggest that SF from the TT joint cannot be 
used to identify OA in the distal tarsal joints.  It appears that information about OA in the 
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distal joints must be collected from the DIT and TMT joints themselves even if 
anatomical communication is present.   
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Chapter 5:  
Future Directions 
 The research of this thesis focused on both imaging and biomarkers of OA in the 
equine tarsus - an anatomic location in the horse that is prone to the development of OA 
and subsequent lameness that limits careers [99].  The focus of this research was twofold: 
1) Imaging of the tarsus with radiography and MRI and 2) Correlating biomarkers of OA 
to disease found by radiographs, arthroscopy (TT joint), gross examination (TT joint), 
and MRI (PIT, DIT, TMT joints).   
In the TT Joint, the amount of OA identified on radiographs was compared to the 
amount of OA identified in arthroscopy and gross examination.  In the PIT, DIT, and 
TMT joints, radiographs were compared to pathology found on MRI.  In the TT joint, 
radiographs were a poor indicator of disease. The TT joint radiographs were all normal or 
showed subtle changes, but arthroscopy and gross examination scores ranged from mild 
to severe. Arthroscopy remains the gold standard to assess the TT joint, allowing direct 
visualization of the cartilage.  Arthroscopy requires general anesthesia that is a risk factor 
for older horses [60] and can be cost prohibitive. In this study, even with the use of 
arthroscopy, additional lesions were found after joint disarticulation.  Additional lesions 
were found in 7 of 11 horses: 4 in the proximity of the synovial fossa of the distal tibia 
and 3 elsewhere in the joint not visible on arthroscopy.  Future studies should also look at 
MRI in the tibiotarsal joint to see the degree of accuracy it provides in identifying 
cartilaginous lesions.  Further research is warranted to determine the impact cartilage 
lesions have on lameness, if they can be identified on MRI, and if there is a biomarker 
that correlates to presence of such lesions.  High-field strength MRI magnets should be 
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used initially to provide the best chance at identifying subtle lesions, and if they are 
identifiable, standing low-field MRI should be evaluated to determine its efficacy.  If a 
standing low-field MRI is a valid imaging modality for this purpose, horses could avoid 
having to undergo general anesthesia.  Additionally, histopathology should be conducted 
on lesions present at the synovial fossae to determine if they represent pathology or are 
variations of normal. 
In the distal tarsal joints, radiographs were significantly better at identifying 
disease than in the TT joint.  Radiographic scores correlated to MRI scores in both the 
DIT and TMT joints.  However in this population of horses, factors that contributed to 
the identification of early OA were: the presence of subchondral bone hypointensity 
(sclerosis) and subchondral bone hyperintensity.  Subchondral bone sclerosis was 
identified on both radiographs and MRI, but the latter allowed identification with higher 
sensitivity.  Subchondral bone hyperintensity is only visualized on MRI, and is not seen 
on radiographs.  100% of the DIT joints and 80% of the TMT joints in the 
moderate/severe OA groups had hyperintensity on MRI, while none of mild OA horses 
had hyperintensity in either distal tarsal joints.  This finding could be crucial in 
identifying moderate/severe OA from early OA.  More research is needed looking at OA 
and the presence/absence of subchondral bone hyperintensity.  Similar to the TT joint 
mentioned above, the use of standing MRI could be very beneficial in this population of 
horses and should also be researched to see if the lower field strength magnets can 
identify subchondral bone hyperintensity.  Therefore, while radiographs had the horses in 
similar categories of overall mild versus moderate/severe OA, MRI was able to pick up 
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specific abnormalities that could allow the clinician to detect OA earlier in the disease 
process, and prescribe treatment and exercise regimes appropriately.  
OA in the distal tarsal joints may have been underestimated on MRI as well.  It 
would be ideal to disarticulate the distal tarsal joints to allow for direct visualization of 
the articular surfaces, and sample for histopathology.  This is extremely difficult in horses 
with OA as bridging osteophytes are present and disarticulation results in iatrogenic 
damage.  
 In terms of biomarkers, more research is needed with a larger number of horses.  
In the TT joint, C2C and IL-6 were the biomarkers that correlated to disease severity.  In 
the DIT joint, BAP, CPII, and C2C were the best, with potential for CTX II, and in the 
TMT joint, CPII was the best biomarker to identify OA severity.  However, only 11 
horses were included in the study.  Further breakdown of groups was made within the 11 
horses to compare mild to moderate/severe disease, further decreasing the statistical 
power.  Future research could use this study design as a template to contribute more 
biomarker results.  Additionally, enrolling horses with a wider range of disease severity 
would be beneficial.  Biomarkers of synthesis were the best in these joints, meaning they 
were still in stages of anabolism.  In end stage OA, catabolism predominates, and 
biomarkers would be expected to change.  It would be nice to follow horses from early/no 
OA to severe/end stage OA and to track biomarkers during disease progression as long as 
possible. 
The volume of SF collected limited the number of biomarkers evaluated in the 
distal tarsal joints.  Future studies could examine the same biomarkers as in this study, as 
well as more direct biomarkers and include indirect biomarkers.  SF was easily collected 
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from the TT joint, so more biomarkers were examined.  Biomarkers that were examined 
in the TT joint but not the distal joints were: direct biomarker C12C, and indirect 
biomarkers IL-1β, IL-6, Il-8, IL-10, and TNFα.  For all the joints, additional biomarkers 
examined in other studies should be considered including matrix metalloproteinases 
(MMPs), and hyaluronic acid (HA) [76; 79; 83; 84; 100-102; 105; 116; 120-124]. 
A large limitation of this research was the lack of true controls.  It is hard to get 
older horses without OA in the tarsus, which is why groups were broken down into mild 
and moderate/severe disease.  It would be ideal to have controls in future studies, but 
similar breakdowns might be necessary as studies using younger horses showed that age 
influenced biomarker values [73; 100].  Also, we did not have the luxury of enrolling 
horses that had lameness localized to the tarsus, so focus was placed on disease severity 
determined by imaging, not lameness.  In future studies, localizing the lameness to the 
tarsus with diagnostic local analgesia would be beneficial to correlate clinical findings to 
imaging and biomarkers, because ultimately, the ideal purpose of sampling biomarkers 
would be for interpretation of disease status in clinical cases. 
A substantial amount of research is still required to understand the role of 
biomarkers and their potential value clinically in the equine tarsus.  To the authors’ 
knowledge, this is the first study examining biomarkers of OA in the TT/PIT, DIT, and 
TMT joints in an older horse population.  We hope this study provides a template for 
future studies.   
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CHAPTER 6: 
 
FOOTNOTES 
 
a IBEX Technologies, Inc. Montréal, Québec. 
b  Serum Pre-Clinical CartiLaps IDS-Nordic. Helve, Denmark. 
c  Microfuge BAP. Quidel Corporation. San Diego, CA. 
d Genorise Scientific, INC. Glen Mills, PA. 
e Omnipaque 240 (Iohexol 518mg/mL) from GE Healthcare, Princeton, NJ. 
f IBM SPSS Statistics Software. Armonk, NY. 
g GraphPad Prism 7.0b. GraphPad Software, Inc. La Jolla, CA. 
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